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Abstract 
Type 2 Diabetes Mellitus is a serious disease with a long duration and considerable associated 
morbidity. It affects a significant proportion of populations around the world irrespective of 
economic status and its prevalence is increasing despite the efforts of clinicians, researchers, public 
health professionals and policy makers. Most epidemiologic research has focused on exploring the 
risk factors associated with this disease. However the present research aims to increase 
understanding of the progression of the disease from initial diagnosis to death. 
Aims 
The aims of this thesis, from a clinical perspective, are to (a) evaluate the trajectory of blood 
pressure as the disease progresses from initial diagnosis to death in a large longitudinal database of 
newly diagnosed type 2 diabetes mellitus patients;, (b) within sub-cohorts based on body mass 
index at time of diagnosis, explore HbA1c trajectories from diagnosis to death, particularly the 
association with treatment intensity; (c) examine the 'obesity paradox'; and (d) investigate gender 
specific effects of smoking on the risks of cardiovascular diseases. In addition the thesis explores 
methodological issues arising with the use of large longitudinal datasets, in particular issues relating 
to missing data and the effectiveness of multiple imputation as a technique to correct for this. 
Methods and Results 
The thesis has used a dataset of 84596 newly diagnosed type 2 diabetes mellitus patients diagnosed 
between 1 January 1990 and 31 December 2005 and followed until April 2007 derived from the 
United Kingdom Clinical Practice Research Datalink. 
Generalised estimating equation models were used to explore the longitudinal trajectories. Cox 
regression models were used to evaluate the gender specific effects of smoking and the obesity 
paradox in relation to mortality risks. Separate models were created for patients with and without 
cardiovascular diseases prior to diagnosis of type 2 diabetes mellitus. All models were adjusted for 
the effects of other potential confounding factors. 
Elevated HbA1c trajectories were associated with use of intensive medication irrespective of body 
mass index at the time of diagnosis. Patients with normal body mass index at the time of diagnosis 
had increased mortality risk compared to obese patients confirming the obesity paradox in type 2 
diabetes mellitus. Those who died during the study had an elevated trajectory of blood pressure 
compared to those who remained alive and this was statistically significant, but not clinically 
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significant. Elevated mortality risks were observed in those with higher and lower levels of systolic 
blood pressure compared to those with normal (130-139 mmHg). Considering diastolic blood 
pressure of 80-84 mmHg as the reference level, diabetic patients with higher levels had significantly 
increased mortality risk. Women who smoked had a higher risk of cardiovascular diseases and 
mortality than men who smoked. 
Conclusion 
Clinical management, which aims to maintain good control over glycemic and blood pressure levels 
in patients with newly diagnosed type 2 diabetes mellitus, is the most important approach to avoid 
or to delay potential complications and improve survival. Special attention should be given to 
women who smoke as they are exposed to increased risks of cardiovascular diseases and mortality. 
Normal weight patients may also need to be managed differently due to the implications of the 
obesity paradox. Individualised management of this disease by joint efforts of clinicians and 
patients is the most important step in curbing this 21st century epidemic. 
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Chapter 1. Introduction 
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1.1: What is Diabetes? 
Diabetes mellitus (DM) is a major public health problem world-wide. It is a significant health care 
challenge of the 21
st
 century. The World Health Organization (WHO) has defined diabetes as a 
metabolic endocrine disorder characterised by chronic hyperglycaemia, with disorders of 
carbohydrate, fat and protein metabolism occurring as a result of deficiencies in insulin secretion, 
insulin action, or both 
1
. As it is an endocrine disorder affecting glucose regulation, the condition is 
characterised by high blood glucose levels. Insulin regulates blood glucose levels in the human 
body by stimulating the uptake of glucose by muscles and organs. Under normal physiological 
conditions, it is a hormone released from the pancreas when blood glucose levels are high. 
However, in diabetic patients, inadequate secretion of insulin from the pancreas, or defective insulin 
utilisation, leads to the development of high blood glucose levels. Figure 1.1 explains the action of 
insulin in normal, as well as in diabetic, patients 
2
. 
Diabetes is usually classified into three types: 
 Type 1 diabetes (T1DM) 
 Type 2 diabetes (T2DM) 
 Gestational diabetes 
T1DM is also known as pancreatic endocrine insufficiency. It is an autoimmune condition. Patho-
physiologically, T1DM occurs due to the destruction of the β cells of the pancreas. Since 
endogenous insulin production is affected, treatment of this type of diabetes requires daily 
administration of insulin. The precise cause of T1DM is still unknown, and according to current 
medical knowledge, it is not preventable and it may be as a result of some viral infections.  
In T2DM (also known as nonpancreatic insufficiency), insulin is produced in normal or even high 
amounts but the response of body cells to insulin is defective, leading to insulin resistance 
3
. Insulin 
resistance is a physiological condition in which cells of the body fail to utilise secreted insulin 
effectively. 
The direct and indirect costs of diabetes management are increasing day by day. Direct costs 
include those associated with medical care, drugs, insulin, self monitoring equipment, and other 
materials. . Indirect costs arise from the reduction or loss of income or reduced quality of life. 
Indirect costs may be higher than direct costs. Cost of diabetes management is about 14 billion 
pounds per year 
4
.   
   
3 
 
Figure 1.1: Insulin action in normal and diabetic patients 
2
. 
 
 
The leading pathophysiological cause of T2DM is the failure of pancreatic β cells. Failure in these 
cells leads to inadequate secretion of insulin, and increased insulin resistance in the liver, fat tissues 
and muscles. Physical inactivity and obesity lead to insulin resistance, increased production of 
glucose by the liver, and decreased glucose uptake in skeletal muscles. In order to compensate, β 
cells increase insulin secretion, but the progressive failure of β cells leads to hyperglycaemia and 
finally Type 2 diabetes Mellitus 
5
. T2DM usually results from a progressive insulin secretory defect 
on background of insulin resistance 
6
. Individuals with T2DM can live with an undiagnosed 
condition for many years. As a result of high blood glucose levels, body organs are damaged during 
this undiagnosed period. Many individuals are diagnosed with T2DM only when they develop 
complications of diabetes. The major complications associated with diabetes are outlined in Figure 
1.2. 
As a chronic disease, complications of DM may affect the functioning of various organ systems, 
and account for much of the morbidity and mortality associated with this disease. These chronic 
complications can be broadly classified into two major categories: vascular and non-vascular. 
Vascular complications are further divided according to whether they are microvascular 
(retinopathy, neuropathy, and nephropathy) or macrovascular (coronary artery disease [CAD], 
peripheral arterial disease [PAD], and cerebrovascular disease). Conditions such as gastroparesis, 
infections, and skin changes constitute the non-vascular complications of diabetes. 
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Figure 1.2: Major diabetes complications 
2
 
 
   
5 
 
The increased risks of vascular and non-vascular diseases are directly associated with the duration 
of hyperglycaemia. Chronic hyperglycaemia remains the major cause of microvascular 
complications. Randomised controlled clinical trials, and epidemiologic studies have convincingly 
demonstrated that a reduction in chronic hyperglycaemia in T2DM patients prevents or delays 
microvascular complications such as retinopathy, neuropathy, and nephropathy 
7-10
. Studies have 
reported an increased risk of cardiovascular disease (CVD) in patients with DM and also reported a 
two to four-fold increase in coronary artery disease events and mortality in patients with T2DM 
8,11,12
. A meta-analysis of intensive glycaemic control, and macrovascular complications in T2DM 
patients also suggests that a strict lowering of glucose levels reduces the risk of major 
cardiovascular events 
12
. Factors such as dyslipidemia and hypertension also play important roles in 
the development of the macrovascular complications of T2DM 
8
. 
Gestational diabetes is a clinical condition observed in pregnant women as a result of insulin 
resistance and subsequent high blood glucose levels. This condition develops as a result of insulin 
action being blocked, probably by placental hormones. Normally, gestational diabetes resolves after 
the birth of the baby. Still, women with gestational diabetes are highly likely to have the same 
condition in subsequent pregnancies and are at higher risk of developing T2DM during their lives. 
1.2: Diagnosis of Diabetes Mellitus 
Usually, diagnosis of diabetes is made on the basis of levels of plasma glucose in the blood, 
measured either with the fasting plasma glucose (FPG) test or the 2-hour plasma glucose (2-h PG) 
level after a 75-g oral glucose tolerance test (OGTT) 
13
. Recently, the American Diabetes 
Association (ADA) suggested the use of glycated haemoglobin (HbA1c) as the preferred method 
for confirming diabetes (using the criterion HbA1c ≥ 6.5%) 13. 
The onset of T2DM in most cases occurs as a latent phase of glucose intolerance or impaired 
glucose regulation (IGR). This condition of impaired glucose regulation is known as pre-diabetes, 
and is characterised by impaired fasting glycaemia and/or impaired glucose tolerance. This pre-
diabetes group is identified as being an intermediate group of individuals whose glucose levels, 
although not meeting the criteria for diabetes, are nevertheless too high to be considered normal. 
These individuals in this group have impaired fasting glucose (IFG) and impaired glucose tolerance 
(IGT) if their FPG levels are between 100 mg/dl (5.6 mmol/l) and 125 mg/dl (6.9 mmol/l), and their 
2-h OGTT values are between 140 mg/dl (7.8 mmol/l) and 199 mg/dl (11.0 mmol/l), respectively. 
These categories are used by the ADA to identify individuals with a high risk of diabetes 
13,14
. 
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HbA1c is the gold standard biomarker for measuring blood glucose levels and thus for identifying 
diabetes status. HbA1c is a laboratory test that measures average blood sugar over a three month 
period. The last three months contributes to the overall HbA1c value, thus justifying considering 
any alteration in HbA1c within the last six weeks to be a result of dietary modification or treatment 
in this period 
14
. The HbA1c cut-off points for disease determination are: less than 5.7% (normal); 
5.7% to 6.4% (pre-diabetes); 6.5% or higher (diabetes) 
13
. 
1.3: The Global Burden of Type 2 Diabetes Mellitus 
T2DM is one of the most common non-communicable diseases and affects 382 million people 
worldwide. In most high-income countries, T2DM is one of the major causes of death, ranking 
fourth or fifth. A comparison of prevalence estimates for 2013 and 2035 is given in Table 1.1 
Table 1.1: Type 2 Diabetes Mellitus and IGT of 20-79 year old adults 
15
 
 2013 2035 
Total world population (billions) 7.2 8.7 
Adult population (20-79 years, billions) 4.6 5.9 
Type 2 Diabetes Mellitus   
 Global prevalence (%) 8.3 10.1 
 Number of people with diabetes (millions) 382 592 
IGT   
 Global prevalence (%) 6.9 8.0 
 Number of people with IGT (millions) 316 471 
 
The number of people with diabetes is increasing rapidly. The prevalence of diabetes across all age 
groups was 2.4% in 2000 
16
. However, according to a recent report by the International Diabetes 
Federation, the global prevalence of diabetes in the year 2013 was 8.3% 
2
, representing a more than 
threefold increase in estimated prevalence over the last decade. The number of diabetic patients is 
currently more than 382 million worldwide, up from 171 million in 2000, and is expected to reach 
592 million by 2035 
2,16,17
 – a 55% increase over two decades, if the trends continue 15. The 
estimated number of deaths associated with diabetes was almost 4 million in 2010. This figure, in 
the adult diabetic population, is estimated to increase by 69%, for developing countries, and 20%, 
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for developed countries, by 2030 
18,19
. These statistics demonstrate that diabetes is a global 
epidemic. 
1.4: Aims of the Study 
As outlined earlier, T2DM is a chronic progressive condition that leads to various serious health 
complications if not managed properly. The dramatic increase in the number of T2DM patients has 
been attributed to lifestyle changes that have occurred over the past five decades. Globalisation has 
resulted in remarkable changes to lifestyle, political systems, environments and human behaviour 
20
. 
It is of major clinical importance to implement lifestyle changes and regular health monitoring to 
improve the quality of life of persons diagnosed with this disease. Disease progression and the 
development of concomitant medical conditions must be addressed in an effective way. 
Risk factors associated with T2DM, such as smoking, blood pressure and obesity, are controllable. 
Imbalances in the glycaemic index of such patients will result in microvascular and microvascular 
complications. 
The United Kingdom Prospective Diabetes Study (UKPDS) showed that cigarette smoking was a 
significant and independent risk factor for coronary heart disease, stroke and peripheral vascular 
disease in people newly diagnosed with T2DM 
21-23
. Various researchers have shown significant 
differences between men and women in mortality and cardiovascular risks 
24-27
 – this need to be 
considered in the context of increasing uptake of smoking by women in some populations. 
Recent clinical trials and epidemiological studies have created concern and confusion over the 
possible adverse effects of rigorous glycaemic control (measured by HbA1c) and over-intensive 
blood pressure (BP) control on vascular events and all-cause mortality (ACM) in people with 
T2DM 
7,9,12,28-42
. High levels of comorbidity may diminish the benefits of achieving tight control, 
owing to the complex interplay of multiple conditions and risk factors, including body weight, BP 
and lipids 
41. Although some studies have explored the effect of baseline or ‘mean’ HbA1c and BP 
on ACM 
38,39,43,44
, the trajectory effects of HbA1c or BP, observed longitudinally over a long period 
of time, on vascular events and ACM are as yet known. 
As diabetes is a progressive disease, robust risk assessments for vascular and other diseases can 
only be achieved by understanding the interchange of longitudinally measured risk factors and 
medications with each other and over time. In addition, recent epidemiological studies have 
reported conflicting results about the possible association between insulin treatment and an 
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increased risk of cancer in people with T2DM 
45-53
. These reports indicate an urgent need to carry 
out a detailed exploration of the long-term dynamics of risk factors and the effects of their possible 
interactions on vascular and other adverse events in people with T2DM, under different treatment 
regimens at a population level. The present study looks at the dynamics of HbA1c as a potential 
indicator of glycaemic variations from a large longitudinal cohort of newly diagnosed T2DM 
patients. While it is acknowledged that other risk factors such as BMI and dyslipidaemia also vary 
over time in these patients, analyses have been limited to baseline measures. 
The present study uses longitudinal primary-care based data, gathered from newly diagnosed T2DM 
patients observed during the period of 1990 to 2005 – obtained from the United Kingdom Clinical 
Practice Research Datalink (UK CPRD). 
The study has both clinical and statistical aims and will address the following clinical questions 
using innovative statistical methodologies to analyse complex longitudinal primary care data. 
The aims are: 
1. To evaluate the evidence that the association between smoking and the risk of 
cardiovascular disease and mortality, among patients newly diagnosed with type 2 diabetes, 
differs by sex in those with and without cardiovascular diseases before diagnosis. 
2. To examine the trajectories of blood pressure in patients with T2DM, in relation to 
mortality. 
3. To examine the obesity paradox in people newly diagnosed with T2DM, with and without 
CVD prior to diagnosis. 
4. To examine HbA1c trajectories, by body mass index (BMI), and how these are associated 
with mortality in patients with T2DM; as well as to investigate the effects of missing data, 
using multiple imputation. 
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Chapter 2. Literature Review 
This chapter is a comprehensive account of the current status of research in the field of diabetes 
mellitus. Each chapter of this thesis contains separate focused literature reviews. In addition, one 
chapter (6) has been published as an article with a literature review that overlaps with Section 2.1, 
and substantial sections of Section 2.2 have contributed to a published article.  
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2.1: Current State of Research: Clinical 
Diabetes is a serious chronic disease that is growing rapidly, affecting nearly 382 million people 
worldwide, and requires continuous medical care once diagnosed 
2,13,15,19,54
. Both T1DM and T2DM 
are associated with a reduced lifespan, largely because of micro- and macrovascular complications 
of the disease 
33,34
. Continuous effort by patients to self-manage their treatment is very important in 
preventing acute complications from arising 
13
. These complications increase in frequency and 
severity as the duration of the disease lengthens. The authors of a recent seven year prospective 
study – evaluating premature mortality and comorbidities in young diabetic patients – concluded 
that patients who became diabetic at a younger age had similar or poorer metabolic control than 
those who were older at the time of their diagnosis 
55
. This study also reported that a significant 
difference in the proportion of younger (56.1%) and older (69.2%) T2DM patients who use oral 
anti-diabetes medications 
55
. 
2.1.1: Risks of cardiovascular disease and mortality in relation to glycaemic levels 
Epidemiological studies have consistently suggested a relationship between glycaemic control and 
vascular events in patients with T2DM. However, results from intervention trials have been less 
conclusive 
9,12,28-32,40,43,56,57
. A meta-analysis by Zhang et al. reported that, in patients with T2DM, 
increased risks of adverse cardiovascular outcomes are associated with chronic hyperglycaemia 
58
. 
The gold standard biomarker to measure glycaemic status is glycated haemoglobin (HbA1c) 
59
. A 
recent study evaluating the diagnostic value of HbA1c suggested that it is predictive of 
cardiovascular disease risk in diabetic patients 
60
. It is also possible for patients to have normal 
levels of HbA1c at the time of their diagnosis, even if their diagnosis had been made on the basis of 
high fasting blood glucose (FBG) or fasting plasma glucose (FPG) levels 
61
. In the United Kingdom 
Prospective Diabetes Study (UKPDS), newly diagnosed T2DM patients who had not previously 
suffered from CVD were found to have reduced HbA1c levels (from 8% to 7%), but this was not 
associated with a reduction in subsequent cardiovascular events 
7,31,33
. The 16% risk reduction for 
myocardial infarction (MI), reported in the UKPDS, was not statistically significant. Three recent 
landmark studies, the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial
28
, the 
ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release 
Controlled Evaluation) trial
29
, and the VADT (Veteran Affairs Diabetes Trial) study
30
, sought to 
determine the effect of lowering glucose to near-normal levels on cardiovascular risk in patients 
with established T2DM. The compelling message from all these studies is that maintaining 
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glycaemic levels at near-normal values for a median of 3.5 to 5.6 years does not reduce 
cardiovascular events within that time frame, with the exception of the progression of albuminuria, 
nephropathy and retinopathy. However, an analysis of 10-year post-trial follow-up results from the 
UKPDS provides a more optimistic view of the potential benefits of glycaemic control 
31,32
. The 
relative risk reduction for MI and ACM were significant in participants who initially received 
intensive glucose lowering treatment compared with those in the conventional treatment arm. 
Consequently the outcome of the debate on the importance of glycaemic control in preventing 
macrovascular complications remains undetermined. 
The trials referred to above used multifactorial treatment strategies. Therefore, the potential risk 
reduction specifically attributable to glucose lowering is difficult to isolate. Doing so would require 
a very large number of patients and a much longer follow-up time. Different pharmacological 
agents and comorbid conditions have varying effects on vascular outcomes, irrespective of the 
extent to which they contribute to glycaemic control. The UKPDS reported a significant interaction 
effect between HbA1c and SBP, with 21% and 11% risk reductions in ‘any diabetes related end 
point’, for 1% and 10 mmHg reductions in HbA1c and SBP, respectively 38. A recent study 
conducted using the General Practice Research Database (GPRD) reported 52% and 79% higher 
risks of ACM associated with lower and higher levels of HbA1c, compared to the HbA1c decile 
with the lowest hazard (median HbA1c 7.5%) 
39
. However, rather than considering the entire 
trajectories for glycaemic measures, researchers considered the updated mean of HbA1c in their 
analyses. Gebregziabher et al. (2010)
40
 explored the time-varying effect of HbA1c trajectories on 
ACM, using a large cohort of T2DM patients from the US Veterans Affairs registry database. The 
baseline HbA1c was associated with a two-fold increased risk of mortality. However, trajectory 
analysis of HbA1c with 8821 patients and an average of 4.5 years follow-up time showed a non-
significant hazard estimate of 7.3 (95% CI: 0.9 – 57.1). The wide confidence interval of this risk 
estimate in a large data set with an overall mortality rate of 15.3% is difficult to understand. 
It is clinically important to understand the ‘residual’ beneficial effect of HbA1c management, after 
eliminating the joint effects of other factors. Addressing uncertainty related to the potential benefits 
of glycaemic control requires a closer look at the trajectories of different related risk factors over 
time. 
A review by Ismail et al. suggests that the glycaemic targets in T2DM patients should be 
individualised – according to age, present status and duration of the disease, micro- and 
macrovascular diseases, and lifestyle – for improved management of the disease and control of 
glycaemic levels 
62
. 
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This implies the need for a longitudinal analysis (at the population level, using a large primary care 
dataset) of the long-term trajectories of HbA1c, as well as other, related risk factors, and the effects 
these trajectories have on disease outcomes, using appropriate statistical techniques to ensure 
robustness of interpretation. 
2.1.2: Benefits of hypertension management in T2DM patients 
Most clinical trials mentioned above also analysed the potential benefit of hypertension 
management in patients with T2DM, with specifically designed treatment arms. Hypertensive 
T2DM patients are at an increased risk of morbidity and mortality from cardiovascular events. The 
estimated prevalence of hypertension in adults with diabetes is 20–60%, which is 1.5–3 times 
higher than that in age-matched individuals without diabetes 
54
. Another important risk factor is 
body weight, which has been directly associated with hypertension and poor glycaemic control. A 
10 kg weight gain during middle age (40-49 years) increases the risk of developing diabetes by a 
factor of 21 
63
. T2DM is frequently accompanied by an advanced age and obesity, both of which 
increase the risk of hypertension, making it difficult to ascribe elevated BP solely to diabetes 
44
. In 
the presence of uncontrolled hypertension, there is a consistent positive association between 
elevated systolic blood pressure and increased risk of micro- and macrovascular diseases 
38,39
. 
However, the BP arms of the ADVANCE, ACCORD and VADT studies have generated 
contradictory messages. The BP arm of the ADVANCE study suggests that the lowering of BP is 
additive with intensive glucose control in reducing the risk of cardiovascular mortality and all-cause 
mortality in people with T2DM 
35
. In that study, intensive BP lowering reduced the risk of 
cardiovascular death by 18%, but did not significantly reduce composite macrovascular outcomes. 
The ACCORD BP study
36
, targeting a systolic blood pressure (SBP) of less than 120 mmHg 
compared with less than 140 mmHg, reported no significant benefit of intensive BP lowering 
treatment on the rate of a composite outcome of fatal and nonfatal major cardiovascular events. The 
VADT findings suggest a significantly higher risk of cardiovascular events in T2DM patients with a 
SBP of 140 mmHg or higher and a DBP of 70 mmHg or lower, compared with normal BP levels 
37
. 
It is important to note here that the ADVANCE trial had no specified BP goals, and the mean SBP 
in the intensive therapy group (135 mmHg), intensive and standard therapies resulted in similar 
levels of systolic blood pressure (127 mmHg). On the other hand, the UKPDS suggested an additive 
effect of glycaemia and BP, with significant benefits achieved by treating both risk factors 
simultaneously 
38
. It is possible that five years is not long enough to observe significant cardiac 
benefits from the normalisation of BP in patients with T2DM, especially when other effective 
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treatments, including statins and aspirin, are frequently used 
36
. This necessitates much longer 
longitudinal data at the population level to better understand these clinical issues. A study by 
Cederholm et al. reported a lower risk of CVD in T2DM patients within a blood pressure range of 
about 130-135/75-79 mmHg 
64
. 
Given the inconsistent conclusions of the above mentioned clinical trials, long-term BP trajectories, 
at a population level, and their relationship to vascular events and ACM should be explored, so that 
management of BP in T2DM patients can be improved. 
2.1.3: BMI, glycaemic control and obesity paradox in T2DM 
It has been shown that obesity plays a major role in the pathophysiology of T2DM and its 
macrovascular complications 
65-67
. It has also been suggested that an adverse metabolic profile in 
patients with normal weight increases the risk of subsequent development of T2DM and other CVD 
65,66,68
. A recent study explored the relationship between obesity, glycaemic control and 
cardiovascular risk factors in T2DM patients who were not receiving insulin treatment and 
concluded that cardiovascular risk factors become more important as patients became more obese 
65
. This study also reported that younger age and more recent onset of the disease were associated 
with higher BMIs, suggesting that the development of an obese condition at an early age could be a 
significant factor underlying the increase in T2DM incidence 
65
. Further, studies have reported that 
individuals of normal weight have a substantial risk of developing T2DM and CVD 
66,68
. These 
risks are attributed to their confrontational metabolic status, which includes insulin resistance and 
other related diseases 
65
. This suggests that it is not necessary to be overweight or obese for the 
development and progression of T2DM. A study by Andersson et al. reported that in T2DM patients 
who were overweight or obese, high HbA1c levels at diagnosis were associated with increased 
cardiovascular and mortality risks 
69
. 
Although the majority of T2DM patients may be obese
70
, recent studies have raised the issue of an 
obesity paradox 
71,72
. The concept of the obesity paradox runs counter to common beliefs about 
T2DM. A study by Carnethon et al. concluded that patients who were of a normal weight at the time 
of their diagnosis with T2DM had higher mortality rates than those who were overweight and obese 
72
. However, potential interaction effects between cardiovascular and glycaemic risk factors were 
not addressed in their analysis. A recent study by Ganz et al. reported a strong and independent 
association between BMI and T2DM diagnosis, with the effect size increasing together with BMI, 
suggesting that the majority of T2DM patients may be obese at the time of their diagnosis 
73
. 
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2.1.4: Cardiovascular and mortality risks in T2DM patients – gender specific effects of 
smoking 
Cigarette smoking is an important chronic disease risk factor in both diabetic and non-diabetic 
populations. Globally, it is recognised as one of the leading causes of premature mortality 
15,74
. In 
the United States, 22% of adults are smokers and cigarette smoking remains a major cause of 
premature death (20 million), according to the latest reports by the National Centre for Chronic 
Disease Prevention and Health Promotion 
74
. T2DM patients who are smokers have higher blood 
glucose levels and less effective glycaemic control compared to their non-smoking diabetic 
counterparts 
75
. 
In T2DM patients, cigarette smoking is directly associated with risks of micro- and macrovascular 
diseases and renal complications, which may result in elevated mortality risks. Various research 
studies have shown that cigarette smoking is an important and self-regulating risk factor for 
coronary heart disease, stroke and peripheral vascular diseases in T2DM patients 
21-23
. A recent 
systematic review and meta-analysis by Quin et al. in diabetic patients reported that cigarette 
smoking is associated with a 48% increased mortality risk, 54% increased risk of coronary heart 
disease, 44% increased risk of stroke, and 52% increased risk of myocardial infarction 
76
. 
Several studies have reported similar risks for cardiovascular mortality in T2DM patients without 
coronary heart disease (CHD) and non-diabetic patients with CHD 
77,78
. A meta-analysis by Kanaya 
et al. reported that men with diabetes suffered from more CHD deaths than women with diabetes 
27
. 
One of the major causes of death in diabetic patients is stroke. According to a recent study in the 
US, the predicted number of stroke-related deaths in women, by the year 2050, will be higher, by 
68000, than that of men, because women have more events of stroke and a lower recovery rate 
79,80
. 
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2.2: Statistical Review 
2.2.1: A snapshot of statistical issues with longitudinal databases 
Longitudinal studies prospectively investigate the same group of individuals over a period of time 
and are of great importance in clinical research. These longitudinal databases serve as knowledge 
repositories, containing a large amount of information on changing health outcomes, concomitant 
risk factors and treatment. Appropriate analyses of these databases potentially facilitates an 
understanding of disease progression and identification of factors which might be useful in slowing 
or reversing this. In particular, primary care databases have special advantages, as they capture 
population level information at the first point of contact patients have for many health problems, 
and, particularly for chronic diseases, the ongoing features of disease and treatment. Interestingly, 
such databases will capture changes in various measures of lifestyle, and their impact on health 
outcomes, including complications. This allows the identification of the effects of lifestyle on 
disease occurrence, as well as the effects of lifestyle changes made at the individual level on health. 
In addition, effects of changes in health policy, such as those aimed at reducing tobacco use, can be 
monitored. 
There are also disadvantages that must be considered in evaluating the validity of findings from 
studies that use primary care databases. These relate to missing or incomplete data issues or loss-to-
follow-up, quality of data management, measurement errors (particularly in risk factors or clinical 
data), and the irregular timing of measurements, which may occur according to disease 
exacerbations rather than routinely. Statistical analyses must also have sufficient flexibility to 
explore non-linear trajectories of risk factors and health outcomes. 
2.2.2: Missing data issues 
Most primary care databases, including the CPRD (former GPRD), have non-trivial proportions of 
missing data for key variables 
51,81 
. Various approaches have been used to deal with missing data in 
large clinical databases. These include complete case analysis (including only patients with 
complete records), exclusion of variables with incomplete data from the analysis, inclusion all 
available data using maximum likelihood based approaches or imputation based approaches 
51,82,83
. 
However, these approaches for dealing with missing data may lead to selection bias, substantial 
reduction in the power of the study, and misleading conclusions 
52,83,84
. Whichever technique is 
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used, there is a possibility that false associations may be shown, or associations which exist may 
fail to be identified or be incorrectly estimated. It is necessary to understand the mechanisms behind 
missing data in order to evaluate the potential for invalid conclusions. 
2.2.3: Multiple imputation of missing data under complex missing patterns 
Multiple imputation is one of the most advanced and powerful techniques for handling missing 
data
84
, and is increasingly used to adjust for missing data in the analyses of longitudinal data 
82,84-90
. 
Despite the increasing use of multiple imputation, its implementation may be complex and very few 
publications provide sufficient detail on the methods used, the underlying assumptions or the extent 
to which the results can be regarded as more reliable than those generated by other approaches 
87,90
. 
The main obstacle for the appropriate implementation of multiple imputation in longitudinal data is 
a lack of understanding of the mechanisms giving rise to missing data. Various categories of 
missingness have been described 
83,91
. Data may be missing at random (MAR) or missing not at 
random (MNAR). MAR is said to occur if the probability distribution of the observed missing 
pattern, given the observed data, does not depend on the values of the unobserved data. MNAR 
occurs if missingness depends not only on the observed data, but also on the unobserved values. In 
health care data, MNAR could arise because of the health states of the patients and residential 
changes. Mental health data is particularly prone to MNAR – people who have been diagnosed as 
depressed are less likely than others to report their mental status. Clearly the mean mental status 
score for the available data will provide a biased estimate of the mean compared to that obtained 
with complete data. One study has suggested that blood pressure data was not recorded randomly in 
the GPRD, as subjects with more blood pressure readings tended to have higher recorded values 
92
. 
Analysis of MNAR data is a considerable statistical challenge that requires modelling of the 
missingness 
93
. Although multiple imputation of missing data which is MNAR can theoretically be 
dealt with, this is rarely discussed in the literature and available multiple imputation software 
almost uniformly assumes MAR 
87,90
. Complications of MNAR adjustment occur because of the 
need to extend the MAR imputation model to include an informative model for dropouts. Carpenter 
et al. (2007) first addressed this issue with simple sensitivity analyses 
94
. They proposed first 
imputing the missing data under MAR and obtaining parameter estimates for each imputed data set 
in the usual way. Then the overall MNAR parameter estimate was a weighted average of these 
parameter estimates, where the weights depend on the assumed degree of departure from MAR. 
Daniels et al. (2008) discussed strategies for Bayesian modelling and sensitivity analysis in order to 
draw inferences from incomplete data under MNAR 
95
. In some settings (based on simulated data), 
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this approach gave results that more closely agreed with those obtained from joint modelling as the 
number of imputations increased. However, these studies did not address the core issue of 
developing a theoretical framework and a standardised protocol for application. 
2.2.4: The measurement error problem 
Longitudinal data, especially clinical databases, have an inherent problem caused by erroneous 
measurements. Random measurement errors in regression covariates bias the estimates of 
regression coefficients towards the null, and can result in a true association being found to be 
statistically non-significant 
96
. Although there are many methods for measurement error correction, 
these methods remain rarely used in analysing longitudinal data, despite the ubiquity of 
measurement error. Most clinical and epidemiological studies that use generalised linear models to 
analyse the longitudinal healthcare data fail to address this critical issue. 
2.2.5: Survival analysis with measurement errors in risk factors (covariates) 
Clinical and epidemiological studies with longitudinal data seek to explore the effects of disease 
risk factors on disease outcome(s). Application of the Cox regression model in these studies is very 
common. However, while fitting the Cox model with time-independent or time-varying covariates, 
adjustments for measurement errors in risk factors is rare. 
Failure time models subject to covariate measurement errors or missing covariates have aroused 
much interest over the past two decades. Several studies have demonstrated the impact of 
measurement errors by deriving the induced hazard function in the presence of covariate 
measurement error and have advocated several methods for drawing inferences 
97-99
. The most 
popular approach in this context is the ordinary regression calibration (ORC) approach. Although 
ORC is approximately valid and efficient for measurement error correction of relative risk estimates 
from the Cox model with time-independent risk factors when the disease is rare, it is not adaptable 
for use with time-varying risk factors. As researchers are more interested in exploring the risks 
associated with time-varying risk factors, it is very important to develop an appropriate 
methodological framework for survival analysis using time-varying covariates with measurement 
errors. There is very limited methodological literature on this topic 
99
. In addition, clinical and 
behavioural risk factor variables may be either continuous or semi-continuous. Correction for 
measurement errors in semi-continuous data is a non-trivial statistical problem. The need to explore 
time-varying effects of various risk factors on disease outcomes requires development of 
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appropriate joint models for survival time and longitudinally observed risk factors with 
measurement errors. Validation and sensitivity analyses of models with continuous and semi-
continuous risk factor data are needed. 
2.2.6: The problem of irregular risk factor measurements 
In most longitudinal health care data, clinical and biochemical measurements are not available in 
equally-spaced periods of time. Data are usually recorded when a particular patient has a clinical or 
laboratory assessment performed for specific reasons. This creates a potential problem for aligning 
data according to a pre-specified timeline common to all patients to facilitate appropriate analyses. 
For example, the HbA1c measurement in diabetes patients reflects the accumulation of blood 
glucose over a period of three months. However, HbA1c data for individual patients are unlikely to 
be available exactly every three months, with the result that it is difficult to create specific time-
aligned data to explore the trajectory of this crucial risk factor over time and to assess the 
consequent outcomes (such as CVD or mortality). 
2.2.7: Survival analysis with irregularly observed time-dependent risk factors 
Most methods described in the literature for joint modelling of irregularly measured longitudinal 
and event time data are quite complex 
10,44
. It is very important to account for the differences in 
observation frequency between individual patients, for example by including time elapsed since the 
last observation. Interaction effects of this time elapsed with time-varying risk factors will 
potentially occur, affecting the interpretation of risk estimates. Unfortunately, clinical and 
epidemiological studies dealing with this aspect are rare. 
2.2.8: Non-linear trajectories of risk factors and survival analysis 
The trajectories of clinical and biochemical risk factors are often non-linear 
100
. For example, 
several epidemiological studies and long-term outcome trials in diabetes have revealed clear non-
linearity in the long-term growth pattern of HbA1c 
31
. Joint modelling of survival time and 
longitudinal risk factor data generally assumes a proportional hazards model for the survival times 
and a linear mixed-effects model for the longitudinal data. The literature is rich in methods 
developed under this framework, which includes both parametric and semi-parametric methods 
101
. 
However, the linear random effects model may not be suitable for the non-linear covariate process, 
and literature is scarce in this field 
100
. Tapsoba et al. (2009) has proposed a polynomial regression 
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model to model non-linearity in covariates, while developing a joint model for time-to-event and 
longitudinal data 
102
. However, this approach lacks generalisability especially when dealing with U-
shaped non-linearity. 
In summary longitudinal studies suffer from problems of missing data, irregular and erroneous 
measurements. The available standard statistical tools are not suitable for addressing these complex 
issues while simultaneously exploring their trajectories of key risk factors and their association with 
events or outcomes. Current longitudinal studies often ignore these issues, with the potential for 
producing misleading results and the subsequent implementation of practices which lack an 
appropriate evidence based. Future research should concentrate on how current methodologies can 
be generalised to improve the accuracy and reliability of the analysis of outcomes in longitudinal 
studies. 
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Chapter 3. The Data 
  
   
21 
 
3.1: Source Data- The United Kingdom Clinical Practice Research Datalink (UK 
CPRD) 
The recent widespread implementation of electronic recording and nation-wide linkage of patient 
data from primary care practices in developed countries has provided an enormous opportunity for 
clinical, epidemiological and health policy research. The Clinical Practice Research Datalink 
(CPRD) is the world's largest computerised database of anonymised longitudinal medical records 
from primary care, linked with other healthcare data, in the United Kingdom (UK). At present, data 
are being collected on about 10 million active patients, from more than 700 primary care practices 
throughout the UK 
103
. The database is used internationally for research by the pharmaceutical 
industry, clinical research organisations, regulators, government departments and leading academic 
institutions. Participating practices are expected to follow a systematic protocol for collecting 
demographic and clinical data. Anonymised data are regularly submitted to CPRD. The accuracy 
and reliability of CPRD data have been accepted internationally, as a result of extensive research in 
the fields of health sciences and epidemiology 
103,104
. 
Complete medical histories of patients are available from as early as 1987 – beginning as the 
General Practice Research Database (GPRD) in 1987, and becoming the CPRD in recent years – 
and entries continue to be updated from routine clinical consultations. Data obtained from patients 
at the time of their consultation with GPs include demographic data (age, sex and registration 
information); medical data, including diagnoses (from routine GP visits, consultations, 
hospitalisations, emergency care), prescription data with date, formulation, strength, quantity, 
indications for all new prescriptions, events leading to the withdrawal of a drug or treatment; and 
data concerning preventative treatments (including vaccinations and prescription contraceptives). 
Other information collected includes smoking, height, weight, pregnancy, birth, death, date of 
entering the practice, date of leaving the practice, and laboratory results. Occurrences of important 
medical events prior to a patient registering with a CPRD centre are also recorded. 
Diagnosis of a disease is entered into the CPRD using Read Codes, which are alphanumeric codes 
derived from a thesaurus of clinical terms that categorises and defines illnesses 
103
. 
3.2: Strengths of CPRD 
One of the major advantages of using this database for research purposes is that, it narrows the 
research to a clearly defined population that will allow a researcher to select comparative subgroups 
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of patients from the same source population. In general, because the database is broadly 
representative of the UK population, selecting patient and control groups from the same cohort will 
result in selection biases being minimised. This enhances the validity of epidemiologic studies and 
thus increases the ability of findings to be generalised 
103
. In addition, investigators can study 
families by, for example, linking health events in mothers and children 
103
. 
The size of the longitudinal databases, as well as the length of time they have been in use, allow the 
investigation of rare diseases that have incidence rates of less than 1 per 10,000 person-years, with 
sufficient statistical power. Good agreement and accuracy have been observed between prescription 
data captured from specialist information and the medical record 
103
. 
The CPRD allows the researcher to access original medical records, providing more complete 
information on the patient’s health history, thus enabling researchers to verify information captured 
on death, and advice from specialists 
103
. 
3.3: Limitations of CPRD 
One of the major limitations of the CPRD is incompleteness of data. Information in the CPRD is 
taken from the medical record obtained by the GP, and it is expected that data submitted by the GP 
will be complete. However, it is possible that all information from specialist consultations and 
hospital admissions may not be entered into the CPRD. Therefore, relevant information required for 
a specific study may be lacking. Some clinics may not maintain complete data on patients, or make 
sufficient effort to enter data as required. Missing data could include communications from 
specialists, discharge summaries from hospitals, and test results from pathology laboratories. Such 
data may be received in hard copy, and extra time is needed for manual entry. Some GP centres 
may only enter information that affects patient care. For example, only abnormal results may be 
entered into the CPRD 
103
. 
Non-significant medical events are more likely to be missed than medically significant diagnoses or 
events. Data on medication given directly to the patient (i.e. not requiring a prescription to be 
written) and hospital treatments are not readily available. The movement of patients from one GP to 
another GP is not captured in this database 
103
.   
   
23 
 
3.4: Data Used for This Study 
Inclusion Criteria: data on 84596 newly diagnosed type 2 diabetes mellitus patients, aged 18-99 
years, who were diagnosed with T2DM between 1 January 1990 to 31 December 2005, and who 
were followed-up on until April 2007. 
Source variables: data includes demographic, anthropometric, clinical and laboratory variables with 
relevant dates, previous medical history, current medication with codes and prescription dates, and 
disease events (including death), together with their dates. 
Demographic and anthropometric measurements include the age at which the patient was diagnosed 
with diabetes, sex, smoking and alcohol consumption status, deprivation score (an indication of 
socio-economic status), weight and BMI. 
Clinical data includes SBP and diastolic blood pressure (DBP) (mmHg). Biochemical 
measurements include HbA1C (%), fructose, albumin, serum creatinine, triglycerides (mmol/L), 
low density lipoproteins (LDL), high density lipoproteins (HDL), and total cholesterol. 
Occurrences of medical conditions such as myocardial infarction (MI), stroke, heart failure (HF), 
coronary heart disease (CHD), peripheral artery disease (PAD), angina, angioplasty, coronary artery 
bypass graft (CABG), neuropathy, retinopathy and renal complications were also available, with 
dates. Medical history included amputations, arthrosclerosis, coma, seizures, multiple sclerosis, 
fractures, revascularizations, and surgeries prior to the diagnosis of diabetes. 
Family histories of cardiovascular events such as MI and hypercholesterolemia were also available, 
though family histories of diabetes were not. Medication data included prescription of metformin, 
sulphonylurea, rosiglitazone, pioglitazone, meglitazone, insulin, statins, beta blockers, angiotensin-
converting enzyme/angiotensin-II receptor blocker (ACE/ARB), aspirin, and Nonsteroidal anti-
inflammatory drugs (NSAIDs). 
3.5: Methods of Data Management and Data Cleaning 
A total of 84596 patient records were obtained by initially screening 84633 patients. Thirty-seven 
patients were excluded as a result of date of death being reported as prior to the date of diagnosis of 
diabetes. The numbers (%) of newly diagnosed T2DM patients in each year are listed below (Table 
3.1). 
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Table 3.1: Yearly distribution of patients who were newly diagnosed with T2DM 
Year N (%) 
1990 1187 (1.4) 
1991 1570 (1.9) 
1992 1708 (2.0) 
1993 1917 (2.3) 
1994 2031 (2.4) 
1995 2371 (2.8) 
1996 2784 (3.3) 
1997 3273 (3.9) 
1998 3985 (4.7) 
1999 4917 (5.8) 
2000 7015 (8.3) 
2001 8958 (10.6) 
2002 10031 (11.9) 
2003 10417 (12.3) 
2004 11278 (13.3) 
2005 11154 (13.2) 
Total 84596 
 
Clinical, anthropometric, and laboratory variables for all individuals were organised into six-
monthly windows to provide longitudinal data for the follow-up period of 17 years from 1990 to 
2007. In cases where an individual have more than one recorded values for the parameters under 
consideration, one representative value within the timeframe of six months was selected. 
Detailed exploration of this longitudinal data identified outliers and clinically implausible values, 
which might have arisen as a result of measurement or data entry error. Values below and above the 
clinically acceptable range were removed from the final dataset of 84596 patients. 
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For patients who remained alive, the last follow-up date was set to 1 December 2007 for censoring 
purposes and obtained the date of death for others who died. Time-to-death was calculated using the 
date of diagnosis and the modified death date (which included the last follow-up date for patients 
who remained alive). 
Time to first cardiovascular event and to onset of use of medications was similarly calculated, with 
a censoring indicator. Cardiovascular disease included MI, stroke, HF, CHD, PAD, angina, 
angioplasty, and CABG. 
A variable was created identifying the oral diabetes drugs (OAD) prescribed; these were metformin, 
sulphonylurea, rosiglitazone, pioglitazone, or meglitazone. 
Patients were categorised according to their use of hypertensive medications, and, more generally, 
cardio protective medications (CPM), which included ACE/ARB, beta blockers or statins. 
During the follow-up, study subjects may have experienced a specific disease condition at different 
time points. Each of these events was recorded as an independent event, together with date of 
occurrence. As a result, a patient may have multiple records of the same disease, but the total 
number of occurrences of each of these events are not directly available from CPRD data. 
Consequently, the total number of occurrences of each of these events had to be separately 
calculated. 
Identification of the true missing cases in longitudinal data 
Missing data is a common occurrence in all longitudinal studies and the CPRD is no exception. 
Missing values may be ‘actual’ as well as ‘not in follow-up’. A missing value is ‘actual’ if the 
timing of the measurement occurs within the follow-up period, but no value is available. In 
longitudinal studies missingness can occur if the patient follow-up time is left or right censored; this 
can be considered as the second type of missingness. The values for this period are also recorded as 
missing. 
The number and percentage of actual missing observations in the anthropometric and clinical data 
over each time point are listed in the Appendix. Each of the individual missing is identified as 
whether it is ‘actual’ or ‘not in follow-up’ using SAS 9.2. 
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3.6: Description of the Demographic, Anthropometric and Clinical Study Parameters 
During the Study 
The study population of 84596 newly diagnosed T2DM patients comprised 45855 males (54.2%) 
and 38741 females (45.8%) with a mean (SD) age of 62.36 (13.27) years. Of these patients, 41482 
(49.0%) were never-smokers, and 13598 (16.1%) were current smokers with 32.1% former 
smokers. A major proportion of the patients consumed alcohol (n=54605; 64.5%). Descriptive 
statistics of the baseline clinical and laboratory parameters are given in Table 3.2. 
 Table 3.2: Descriptive characteristics of 84,596 newly diagnosed T2DM patients at the time of 
diagnosis 
  N Mean or % Range 
Age 84596 62.4 (13.3) 18 to 99 
Male* 45855 54.2  
Female* 38741 45.8  
Smoking status*    
 Never 41482 49.0  
 Former 27125 32.1  
 Current  13598 16.1  
Alcohol consumption*    
 None 19238 22.7  
 Former users 2963 3.5  
 Current users 54605 64.5  
Deprivation score ** 84621 19.05 (24)  
Height (m) 18405 1.68 (0.10) 1.12 to 2.22 
Weight (kg) 50928 86.25 (19.45) 30.4 to 295 
BMI (kg/m
2
) 49292 30.55 (6.24) 15.2 to 95.3 
SBP (mmHg) 58370 141(19) 62 to 244 
DBP (mmHg) 58368 81 (10) 30 to 170 
HbA1c 38175 7.85(1.96) 1.3 to 21.2 
    HbA1c**  7.3(2)  
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LDL 13917 2.91(1.04) 0.2 to 14.3 
HDL 16696 1.23(0.42) 0.2 to 17.0 
Triglycerides** 22062 1.80(1) 0.2 to 24.9 
Total cholesterol 23280 5.15(1.43) 0.8 to 20.7 
 * n (%), ** Median (IQR) 
Baseline distributions, by gender, of continuous anthropometric, clinical and biochemical study 
parameters have been examined using kernel density plots. This particular method is commonly 
used to smooth sample data into a continuous probability density function. In this procedure, a 
known density function (the kernel) is averaged across the observed data points to create a smooth 
approximation. 
The kernel density estimate, f (n), of a set of n points of density f is defined as: 
 
 
where K is the kernel function h is the smoothing parameter. 
In constructing the kernel density plots, the Epanechikov kernel was selected. The possible 
differences in the distributions of individual parameters, by gender, were tested using a non-
parametric Mann-Whitney test. Significance levels (P values) are displayed in the individual density 
plots in Figure 3.1 (Fig: 3.1A to Fig: 3.1N). 
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Figure 3.1: Density plots of anthropometric, clinical and biochemical parameters 
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3.7: Prior Clinical Conditions and Family History 
Of the 84596 patients, 2.8 % (n=2380) had a history of myocardial infarction (MI), 3.7 % (n=3172) 
had had stroke, 5% (n=4221) had had heart failure, and 10.3% (n=8732) had had coronary heart 
disease (CHD). Nearly 2.3% (n=1948) previously suffered from peripheral artery disease (PAD), 
and 11.4% (n=9650) of the patients had had angina. Only 1% (n=881) had had angioplasty 
performed, and nearly 2% (n=1956) had undergone coronary artery bypass graft (CABG) surgery 
(Table 3.3). Approximately 23% of the patients (n=19432) had had some type of cardiovascular 
event, and approximately 1% of the patients had a family history of angina and/or MI (Table 3.3). 
Over the follow-up of 17 years in T2DM patients, it is possible to develop different cardiovascular 
events such as MI, stroke, HF, CHD, PAD etc. Those who had a history of these diseases prior to 
the diagnosis of T2DM have a greater chance of developing them again. A new variable was 
created (both CVD) to indicate whether the patient had experienced any CVD solely prior to the 
diagnosis, during the follow-up or both. 
M 
N 
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Table 3.3: Description of Previous Medical History in the Cohort. 
Previous medical history n % 
MI 2380 2.80 
Stroke 3172 3.70 
Heart failure 4221 5.00 
CHD 8732 10.3 
PAD 1948 2.3 
Angina 9650 11.4 
Angioplasty 881 1.0 
CABG 1596 1.9 
Any cardiovascular event* 19432 23.0 
Neuropathy 2866 3.4 
Family history   
MI 885 1.0 
Angina 638 0.8 
Hypercholesterolemia 126 0.1 
Any cardiovascular event*: (MI or stroke or HF or CHD or PAD or angina or angioplasty or 
CABG) 
 
3.8: Event Data 
Calculation of time-to-event data: 
The time to all clinical and non-clinical events relevant to this study, as well as death, were 
available in the original CPRD database. This information was collected from various sources, 
including GP diaries, hospital records, etc. Time-to-event was calculated in days by subtracting the 
date the patient was diagnosed with diabetes from the date the first event under consideration was 
reported. 
Approximately 3.4% of patients (n=2873) had experienced at least one non-fatal MI, and 5.4% 
(n=4600) had suffered at least one non-fatal stroke during the follow-up period. Approximately 
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5.6% (n=4726) of patients had had at least one episode of heart failure, 2.5% (n=2078) had PAD, 
and about 8.5% (n=7191) had CHD. Nearly 17.8% (n=15050) had had at least one of these 
aforementioned cardiovascular events or diseases. Almost 6.9% (n=5840) of the patients had angina 
and 0.8% (n=689) had undergone angioplasty. 5% (n=4186) of patients had developed cancer. A 
total of 11084 (13.1%) patients died during the follow-up period after diagnosis of diabetes. Details 
on the events are presented in Table 3.4. 
Table 3.4: Description of current clinical events and all-cause mortality in patients with 
T2DM 
Event Proportion of patients with 
at least one event n (%) 
Median (range) no. 
of events during the 
follow-up* 
Median time to first 
event (Days)* 
Non-fatal MI 2873 (3.40) 2 (17) 1108 
Non-fatal Stroke 4600 (5.40) 2 (30) 1053 
Heart failure 4726 (5.6) 1 (31) 973 
PAD 2078 (2.5) 1 (10) 1018 
CHD 7191(8.5)  926 
Angina 5840 (6.9)   
Coronary 
angioplasty 
689 (0.8)   
CABG 826 (1.0)   
Any CVE 16659 (19.7)   
Cancer 4186 (4.90)  1112 
Death 11084 (13.1)  1259 
* Median (range) no. of events during the follow-up and median time to first event is calculated for 
each study parameter separately. ** Any cardiovascular event (CVE): MI, stroke, HF, CHD, PAD, 
angina, angioplasty, or CABG. 
3.9: Medication Records During the Follow-Up 
More than 74% of the patients had been treated with at least one oral anti-diabetes drug, with 
approximately 63% (n=52846) and 46% (n=38609) on metformin or sulphonylurea, respectively. 
Approximately 34.2% (n=28958) had been taking both metformin and sulphonylurea. About 11% 
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of the patients had been taking rosiglitazone at some stage during the follow-up. Only 4% of the 
patients had been treated with pioglitazone. Of the 84596 patients, 11.7% (n=9909) had been treated 
with insulin of any kind during the follow-up period (Table 3.5), though information regarding the 
type and doses was not available. Almost 10.5% (n=8895) of patients had been taking insulin with 
at least one OAD. 
The majority of patients (71%, n=60033) had been undergoing statin treatment, with about 64% 
(n=53986) on ACE/ARB and about 34% (n=28604) on beta blockers (Table 3.5). A large 
proportion of subjects (70.9%; n=59972) had been taking either type of hypertensive medication 
(beta blockers or ACE/ARB) during the follow-up period. T2DM patients in this study cohort were 
taking different medications for different clinical conditions at the same time, i.e., an individual 
who have been diagnosed with T2DM may suffer from other concomitant diseases such as 
hypertension, dyslipidaemia etc. and be receiving medications to control each of these clinical 
conditions. 
Table 3.5: Record of current medication in the patients with T2DM 
Current medication n % 
Metformin 52846 62.5 
Sulphonylurea 38609 45.6 
Rosiglitazone 9486 11.2 
Pioglitazone 3319 3.9 
Meglitazone 970 1.1 
Any Oral anti-diabetic drug 62689 74.1 
Insulin 9909 11.7 
Statins 60033 71.0 
Beta Blockers 28604 33.8 
ACE/ARB 53986 63.8 
Any hypertensive medication 59972 70.9 
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3.10: Longitudinal Data 
Seventeen year longitudinal data of anthropometric, clinical and biochemical parameters for the 
newly diagnosed T2DM patients from UK CPRD are arranged in six-monthly time window. The 
longitudinal distributions of these study parameters over the entire follow-up period are presented in 
Figure 3.2 (Figures 3.2A to 3.2R), using mean (SE) or median (IQR), as appropriate, for the whole 
cohort, as well as by gender. 
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Chapter 4. Gender Specific Effects of Smoking in T2DM Patients 
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Evaluation of the gender specific effects of smoking on cardiovascular and mortality outcomes 
among newly diagnosed diabetic men and women 
4.1: Background 
Cigarette smoking has caused a major and avoidable public health disaster across the world, in both 
developed and developing nations. According to a recent report by the National Centre for Chronic 
Disease Prevention and Health Promotion, more than 20 million premature deaths have been caused 
by cigarette smoking 
74
. According to that report, 22% of adults in the US are smokers. The 
causally-linked damage that cigarette smoking has on various human organ systems is depicted in 
figure 4.1. As is clear from the figure, smoking affects all organs of the body, resulting in drastic 
quality of life reductions. Smoking is a modifiable risk factor for many chronic diseases, such as 
cardiovascular disease, cancer, chronic lung disease, asthma, and diabetes. Type 2 diabetes mellitus 
is a multifactorial, chronic, non-communicable disease. Recent increases in the prevalence of 
T2DM patients have been attributed to a dramatic increase in overweight and obese persons in both 
high- and low-income countries 
66
. Research has shown that smoking is associated with higher risks 
of T2DM. The driving forces behind the increased risks are insulin sensitivity, accumulation of 
abdominal adipose tissue, and pancreatic β cell dysfunction. The effect of smoking on T2DM can 
be influenced by physical status such as being overweight 
105
. According to a study by Patja et al. 
on middle aged Finnish men and women, smoking is highly detrimental in patients with higher 
BMIs 
106
. 
4.1.1: Cardiovascular disease risks in T2DM patients 
Cigarette smoking is an important chronic disease risk factor in both diabetic and non-diabetic 
populations. Globally, it is recognised to be one of the leading causes of premature mortality 
15,74
. 
The major cause of mortality in patients with T2DM are cardiovascular (microvascular, 
macrovascular) and renal complications, which are directly related to cigarette smoking. As a result, 
smoking further exacerbates the increased mortality risk of patients with diabetes. The United 
Kingdom Prospective Diabetes Study (UKPDS) showed that cigarette smoking was a significant 
and independent risk factor for coronary heart disease, stroke and peripheral vascular disease in 
people newly diagnosed with T2DM 
21-23
. A recent systematic review and meta-analysis of diabetic 
patients reported that cigarette smoking is associated with a 48% increased mortality risk, 54% 
increased risk of coronary heart disease, 44% increased risk of stroke, and 52% increased risk of 
myocardial infarction 
76
. 
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Figure 4.1: The health consequences causally associated with smoking 
74
 
 
4.1.2: Gender differences in the association between cigarette smoking and coronary heart 
disease and stroke 
Studies have shown that cardiovascular mortality in T2DM patients without coronary heart disease 
(CHD) is same as that of those with CHD and without T2DM 
77,78
. Differences between gender, in 
the mortality risk observed in patients with CHD, women having poorer prognoses than men 
107
. 
Older age, occurrences of major comorbid conditions, and clinical conditions that are clinically 
difficult to manage are some of the major reasons behind poor outcomes in women who had CHD 
27
. 
A major cause of death in diabetic patients is stroke. According to a recent report conducted in the 
US, the predicted number of deaths from stroke in women by 2050 will be higher, by 68000 deaths, 
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than that of men due to the higher number of events and lower recovery among women 
79,80
. Gender 
differences in stroke cases have been observed in epidemiological studies, and successful 
prevention and management options have been significantly affected by this gender difference 
79
. 
There are a number of reasons underlying the adverse effects of T2DM being more significant in 
women than in men. The longer life expectancy of women compared to men could be one of the 
reasons why women suffer a higher number of strokes than men 
108
. According to other studies, the 
sources of gender differences in cardiovascular disease risks are differences in levels of the risk 
factors of cardiovascular diseases. For example, T2DM women had significantly higher blood 
pressure levels and lipid profiles than men with T2DM 
24
. Another possible reason for the higher 
risk in diabetic women is that women with T2DM may be less likely to receive appropriate 
treatment 
109
. 
Coronary artery disease is one of the major causes of death among both men and women 
110
. 
Previous studies have shown that the relative risks of CHD and mortality, in relation to T2DM, 
were higher in women than in men when compared to their diabetes-free counterparts. Previous 
studies have also shown that the relative risks of fatal CHD attributed to T2DM were 50% higher in 
women than in men 
24
. Smoking is considered an important risk factor for arterial hypertension and 
diabetes management 
111,112
. 
4.1.3: Impact of smoking cessation on cardiovascular risk in individuals with and without 
diabetes 
The meta-analysis conducted by Willi et al. (2007), based on 25 prospective cohort studies (1.2 
million patient records), reported a 44% (95% CI of rate ratio: 1.31, 1.58) increased risk of incident 
diabetes (T2DM) associated with active smoking 
113
. Fagard (2009) reported a significantly 
increased risk of mortality and coronary heart disease (CHD) associated with smoking in patients 
with hypertension and diabetes 
111
. 
However, smoking cessation, after ten years, normalises the subsequent risk of CHD to values 
similar to those of never-smokers 
114-117
. A study by Chaturvedy et al. on diabetes patients showed 
that the all-cause mortality risk in former smokers was 50% higher for patients who stopped 
smoking within the previous nine years and 25% higher for individuals who stopped smoking more 
than ten years prior, compared to those who had never smoked 
117
. This study also showed that risks 
remained high several years after quitting smoking and were highly dependent on the duration of 
   
48 
 
smoking 
117
. Another study by Kengne et al. has shown that, irrespective of diabetes status, smoking 
cessation was associated with a 19% reduction in cardiovascular risk 
118
. 
4.2: Objectives 
The objectives of this chapter are to: 
1. quantify the risk of cardiovascular diseases and all-cause mortality associated with current 
smoking, separately for women and men with diabetes. 
2. determine whether there are significant gender differences in the relationship between 
smoking and cardiovascular outcomes, and all-cause mortality in individuals with diabetes. 
3. examine the benefits of smoking cessation on the risk of cardiovascular diseases and all-
cause mortality in men and women with diabetes. 
4.3: Methods 
4.3.1:Data 
The Clinical Practice Research Datalink (CPRD) is a large proprietary, anonymised, longitudinal 
dataset derived from primary care in the United Kingdom. The CPRD contains clinical information, 
including diagnoses, mortality, laboratory results and prescription data 
119,120
. The primary data set 
for this retrospective cohort study includes data from 84596 individuals, aged 18 to 99 years, who 
were newly diagnosed with T2DM between January 1990 and December 2005, and who have been 
registered with their general practice for at least 12 months 
121
. Rigorous classification techniques 
were used to ensure the correct identification of patients with T2DM (Chapter 3). The following 
information was extracted: age, gender, smoking status (defined as current, former or never 
smoker), BMI, blood pressure recordings (systolic and diastolic), HbA1c, lipid measurements, 
history of cardiovascular diseases before the diagnosis of diabetes; the recorded clinical events 
during follow-up included CVD (myocardial infarction, stroke, heart failure, angina, coronary heart 
disease, peripheral arterial disease, and conditions requiring angioplasty or coronary artery bypass 
graft), diabetic neuropathy, renal complications, along with dates of events. The date of death was 
derived from modified GPRD death codes. Specific disease Read codes capture data as part of 
routine care (including investigations) or as a result of hospitalisation or emergency care 
120,122-124
. 
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Among these 84596 individuals, 82205 had complete data on smoking status at diagnosis of 
diabetes, as well as complete data on other demographic information. The data for prescribed 
medications, with prescription dates, after diagnosis of diabetes—including use of oral anti-diabetes 
drugs, ACE/ARB, beta blocker, statin and other concomitant medications—were obtained. The 
patients who were prescribed with any one of ACE/ARB, beta blockers or statins were, collectively, 
categorised as patients under treatment with cardio protective medications. The patients who were 
taking either ACE/ARB or beta blockers were defined as patients under treatment with hypertensive 
medications. 
Ethics approval for the use of CPRD data was granted by the Independent Scientific Advisory 
Committee in June 2014. 
4.3.2: Statistical Methods 
Summary statistics for the study population are presented by number (percentage), mean (SD) or 
median (IQR), as appropriate. Differences between the smoking groups were tested with Student’s 
t-test for near normally distributed continuous variables and the Pearson chi-square test for 
categorical variables. Separate Cox regression models were used to evaluate the risk associated with 
smoking (current versus former, and current versus never) for each of the cardiovascular events and 
all-cause mortality during follow-up. All Cox models were tested for the proportional hazard 
assumption and satisfied this assumption. 
In order to quantify the risk associated with each of the individual components of the cardiovascular 
disease under consideration, multivariate models were fitted separately for all patients and for 
patients with and without a previous history of cardiovascular disease. Patients with previous 
cardiovascular disease would be more likely to have more attention given to their medical condition 
and disease progression. 
Gender specific risks were estimated using the lincom statement in Stata, which calculates the 
individual effects as a linear combination of estimators of coefficients of model terms. The P-values 
used in the test for interaction between gender and smoking are given in the text, together with 
gender specific hazard ratios. Separate models were used for mortality and each of the 
cardiovascular events, after adjusting for the effects of age, alcohol consumption, baseline BMI, 
baseline HbA1c, treatment with OADs, hypertensive medications and cardio protective 
medications. The gender specific absolute risks and adjusted risk difference associated different 
smoking behaviours had calculated separately for men and women.   
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4.4: Results 
In the study cohort (n=82205), 45.5% were female, with a mean (SD) age of 64 (14) years; the male 
cohort was younger, with a mean age of 61 (12) years. The characteristics of the population, by sex 
and smoking status, are given in Table 4.1. In general, at their time of diagnosis with T2DM, 
women were more likely than men to be older, marginally obese, and had significantly higher levels 
of SBP, LDL, and HDL than men. A subgroup analysis by gender and smoking status also 
supported the finding that women recorded higher values for these clinical measurements than men. 
However levels of DBP, HbA1c and triglycerides were higher in men at the start of the study. The 
proportions of current smokers (60%) and former smokers (67%) were higher in men. Distributions 
of all baseline demographic characteristics, clinical histories, laboratory measurements, and 
medications during the follow-up are presented in Table 4.1, separately for men and women and by 
smoking status. 
The proportion of never, former and current smokers who had MI during the follow up was higher 
among men compared to women (2.57 vs 3.56, 3.07 vs 4.56% and 2.90 vs 3.54%). CHD was higher 
in all the three smoking categories (never, former and current) among men compared to their 
women counterparts. The combined cardiovascular disease event (any cardiovascular event) was 
higher among current smoking men (n=1582, 19.26%) compared to currently smoking women 
(n=899, 16.69%). Similarly the proportion of patients with any CVD was higher in men for former 
smokers and never smokers compared to their respective women counterparts.  The consumption of 
oral anti diabetes drugs, hypertensive medications and cardio protective medications during the 
follow-up were similar between men and women.  
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4.4.1: Association between smoking and cardiovascular outcomes in individuals without a 
prior history of CVD by gender 
i. Current smokers vs. former smokers 
In patients without a history of a cardiovascular disease prior to the diagnosis of T2DM, women 
who are current smokers had significantly higher risk of MI, compared to current smoking men and  
women who were former smokers (HR, 95% CI: 6.66, 2.32-19.11, P-value:<0.001). However the 
mortality risk was higher among men (HR, 95% CI of HR:1.58, 1.26-1.97 ) compared to women 
(HR, 95% CI: 1.42, 1.08-1.85, P-value:<0.001), (Table 4.2, Figure 4.2). 
ii. Current smokers vs. never-smokers 
The analysis of current smokers against never-smokers suggested that women who currently smoke 
face a higher risk of cardiovascular disease and death compared to men who currently smoke. In 
patients without a prior history of CVD, a significantly higher risk of MI, heart failure, CHD and 
death was reported among women who smoke. The risk associated with PAD was significantly 
higher in men (HR, 95 % CI: 4.7, 1.52-14.49, P-value:<0.001) compared to women (HR, 95 % CI: 
3.1, 0.75-12.41) (Table 4.2, Figure 4.3). 
Among patients without a history of CVD, the interactions between gender and being a former 
smoker on the risk of heart failure and mortality were significant (P < 0.01 for both). Significant 
interactions between gender and current smoking were observed for the risks of MI and mortality (P 
< 0.05, P < 0.01, respectively). Other cardiovascular diseases showed no such interactions. 
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4.4.2: Association between smoking and cardiovascular outcomes in individuals with a prior 
history of CVD 
I. Current smokers vs. former smokers 
In patients with history of a CVD prior to their diagnosis with T2DM, women who smoked had a 
significantly higher risk of MI (HR, 95% CI: 1.90, 1.16-3.13, P = 0.01) than men. The risks 
associated with PAD (HR, 95% CI: 1.68, 1.28-2.20, P < 0.001) and mortality (HR, 95% CI: 2.04, 
1.41-2.96, P-value:<0.001) were higher in women compared to men. (Table 4.3, Figure 4.4) 
II. Current smokers vs. never-smokers 
In this comparison, significantly higher hazard ratios were observed in women, for both PAD (HR, 
95% CI: 2.87, 2.19-3.77, P < 0.001) and mortality (HR, 95% CI: 2.43, 1.72-3.44, P < 0.001) than 
men (Table 4.3, Figure 4.5). 
In patients who had had CVD prior to their T2DM diagnosis, a significant interaction between 
gender and current smoking was observed for mortality. 
The gender specific adjusted risk difference per 1000 person years among former smokers and 
current smokers according to their cardiovascular disease status is given in Table 4.4 and Table 4.5. 
In patients without cardiovascular disease prior to diagnosis women reported higher cases of 
individual cardiovascular diseases per 1000 person years. The adjusted risk differences for MI in 
women among former and current smokers were almost 5 and 6 per 1000 person years compared to 
their never smoking counterparts. Similarly the risk difference associated with mortality was higher 
in women by 26 per 1000 person years among current smoking diabetes patients. In patients with 
cardiovascular disease prior to the diagnosis of T2DM, mortality risk difference was higher in 
women who were former (35 vs 19) and current (48 vs 18) smokers per 1000 person years 
compared to never smoking diabetic patients. 
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Multivariate Cox regression models for CVD and mortality risks suggest that diabetic women who 
smoke are at a higher risk of these diseases, after adjusting for the effects of age at diagnosis, 
alcohol consumption (never, former and current), baseline measurements of BMI, HbA1c, and the 
consumption of OADs, hypertensive medications and cardioprotective medications.  
Smoking cessation in those who were free from prior CVD results in the significant reduction, by 
15%, of the risk of MI. Similarly, smoking cessation was associated with 51% and 30 % reductions 
in mortality risk in those with and without prior episodes of CVD, respectively. 
4.5: Discussion and Conclusion 
In a large, population level cohort of patients with newly diagnosed T2DM, with 5.4 years of 
median follow-up, smoking, irrespective of status (former/current, versus never-smokers), was 
associated significantly with an increased risk of cardiovascular events and all-cause mortality in 
women who have histories with and without CVD prior to their diagnosis with T2DM. Thus, 
cigarette smoking increased what were already elevated cardiovascular and mortality risks. 
Key strengths of this analysis include a large sample – taken from routine clinical practice with over 
5.4 years follow-up – of individuals with T2DM, complete (non-missing) data on smoking status at 
the time of diagnosis, detailed information on medications and cardiovascular events, and a focus 
on mortality. Further, complete and reliable descriptions of cardiovascular events, along with the 
times that they occurred were also available. The use of multivarite modelling techniques, to 
account for the evaluation of risk factors, added further strength to the robustness of the estimates 
obtained in this analysis. 
The limitations of this study include the non-availability of data regarding (1) smoking status at the 
end of the study, (2) frequency of smoking, (3) adherence to medications during the follow-up 
period, and (4) some demographic variables such as ethnicity. This analysis also could not account 
for changes in smoking behaviour over the follow-up time. 
In this analysis, the gender specific effects of smoking on CVD and mortality suggest an increased 
risk among diabetic women compared to men, which is consistent with other epidemiological 
studies of gender specific effects 
24,125,126
. When gender specific effects of smoking were compared, 
there was some evidence to suggest a stronger coronary and mortality hazard in women, when 
compared with men. This is consistent with the findings from previous reviews of the gender 
specific impact of coronary risk in both diabetic patients and the general population 
24,76
. The 
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mechanisms which might account for the higher risk of CVD and death in women who smoke 
(current and former) compared to men is presently unknown. One potential explanation for this 
could be undertreatment of T2DM in women compared to men. Although this study does not 
provide any evidence to support this hypothesis, a study on gender desparities in treatment of 
cardiac risk factors in diabetic patients concludes that women with diabetes receive less treatment 
than diabetic men 
127
. 
A meta-analysis by Qin et al. reports that diabetic smokers have higher risks of MI, stroke, CHD 
and all-cause mortality than their non-smoking counterparts 
76
. Another meta analyses by Huxley et 
al. on the gender stratified risk of coronary heart disease in patients wth cigarette smoking 
concluded that smoking women had a significantly (25%) increased risk of coronary heart disease 
than men 
126
. 
Studies have reported that patients with diabetes have an increased risk of MI 
128,129
. The mortality 
risk due to MI is double than that of their non-diabetic counterparts  
128
. The risk for MI associated 
with smoking is higher in diabetic patients 
129
. Nilsson et al. (2009) 
129
 observed a 70% increased 
risk of first-incident fatal/non-fatal MI among smokers. In this study, for both all patients 
(n=82205) and patients without prior CVD (n=63166), current smokers had a 30% (95% CI of HR: 
1.16, 1.46) and 77% (95% CI of HR: 1.35, 2.31) increased risk of MI compared to never-smokers. 
In former smokers, the risk for MI was higher by 21% (95% CI of HR: 1.10, 1.32). 
Patients with T2DM have 2- to 5-fold increased risk of stroke compared with those without diabetes 
130
. The UKPDS
22
 and FIELD
131
 studies have explored the association of smoking with the risk of 
stroke in patients with T2DM. Hankey et al. (2012)
131
 observed that older patients with a history of 
stroke were at the highest risk of stroke. They reported a 52% increased risk of stroke associated 
with current smokers (combining patients with/without prior stroke). In this study, with all patients 
(n=82205) current smokers had a 26% increased risk of stroke (95% CI of HR: 1.15, 1.38), which 
was similar to the risk observed in patients without prior CVD (n=63166). However, among 
patients with a history of vascular diseases before the diagnosis of diabetes, smoking was not 
associated with any significant increase in the risk of stroke (95% CI of HR: 0.93, 1.16) after 
adjusting for various risk factors including age. 
Studies have reported that cardiovascular diseases have developed 7 to 10 years later in women 
compared to men, and it is important to mention that CVD remain as a major cause of death in 
women above 65 years 
132
. As a result of misunderstanding that pre-menopausal women are  
‘protected’ against cardiovascular disease, the real risk in women is underestimated. Research by 
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Towfighi et al. reported that the prevalence of MI has increased in midlife women aged 35 to 54, 
but in men the prevalence has  declined 
133
. The possible biological mechanisms for women to be at 
higher risk of cardiovascular diseases relate to the hormonal, genetic and metabolic differences 
between men and women 
134
.  
Another interesting observation in this analysis is the significantly increased risks of major 
cardiovascular events associated with smoking in patients without any CVD prior to their diagnosis 
with T2DM (Table 4.2). The comparisons across different smoking categories (current versus 
former smokers, current versus never-smokers), based on their prior cardiovascular disease history, 
suggest sub-optimal management of diabetes in patients without such an event. It is possible that 
the patients in this group, irrespective of smoking category, fail to maintain good compliance with 
protective medications. 
This study uses a large, longitudinal primary care dataset with median follow-up of 5.4 years to 
address the recent controversial issue of gender specific risks associated with CVD and mortality in 
patients with or without a cardiovascular event prior to T2DM diagnosis. The conclusions are that 
(1) women who are exposed to smoking (current/former smokers versus never-smokers) are at a 
higher risk to CVD and mortality than men; (2) in the absence of a CVE prior to T2DM diagnosis in 
these patients there remains an increased risk of a CVE and mortality in women compared to men; 
(3) patients who smoked (current or former smokers) and had a CVE before their diagnosis with 
T2DM also had amplified risks compared to never-smokers, the risk in these patients being slightly 
lower than that of the patients without a prior CVE, posssibly due to the effect of cardio protective 
medications. 
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Chapter 5. Blood Pressure Trajectories Before Death 
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Trajectory analysis of blood pressure before death in patients with type 2 diabetes 
5.1: Background 
Hypertension is a commonly occurring comorbid condition in diabetes cases, affecting a significant 
proportion of patients. Guidelines for the treatment of hypertension in patients with type 2 diabetes 
recommend maintaining a systolic/diastolic blood pressure below 140/80 mmHg 
135
. Anti-
hypertensive medications, along with lifestyle modifications, are advised for patients with a blood 
pressure above 140/80 mmHg. Exploratory analyses of data taken in the Action in Diabetes and 
Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial reported 
that additional lowering of blood pressure by 5.6/2.2 mmHg in patients with type 2 diabetes was 
associated with 18% and 14% reductions in CVD and all-cause mortality respectively, when 
compared with placebo 
136
. However, an analysis of Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) trial data showed no benefit of tighter blood pressure control in patients with 
T2DM 
36
. The meta-analysis conducted by McBrien et al.
137
 reported no significant association 
between intensive blood pressure lowering and mortality in patients with T2DM. Similarly, a recent 
systematic review conducted by Jicheng et al.
138
 reported no clear benefit of intensive blood 
pressure control on mortality. Further, a retrospective cohort study on about 126,000 newly 
diagnosed patients with T2DM reported that a systolic/diastolic blood pressure below 130/80 
mmHg during the year following diagnosis with diabetes was not associated with improved survival 
139
. However, information regarding changes in blood pressure over time and its possible effects on 
mortality are very limited. 
Only a few studies have examined the blood pressure trajectories of people with diabetes. A post 
hoc analysis of UKPDS data reported a significant risk reduction in mortality, by 9-16%, for every 
10 mmHg decrement in systolic blood pressure 
38
. This study explored the updated mean blood 
pressure observed over time, and not changes in blood pressure over time. The VADT study 
reported increased risk of cardiovascular events associated with the joint effects of high systolic and 
diastolic blood pressure over a period of 7 years 
37
. However, two recent studies have suggested that 
lowering blood pressure can increase mortality in patients with T2DM 
140,141
. In a small cohort of 
326 elderly patients (older than 75 years), van Hateren et al.
140
 reported significant increases (15% 
and 22%) in mortality risk for each 10 mmHg decrease in systolic and diastolic blood pressure, 
respectively. However, in the cohort of 555 patients aged between 60-75 years, no association 
between blood pressure and mortality was observed 
140
. Another study, based on a cohort of 3766 
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patients who had had T2DM for 3 years, reported that the rate of decline of blood pressure was 
more rapid in those people who died than those who remained alive 
141
. 
Although analyses from both studies adjusted for various confounding factors, including 
medications, the robustness and generalisability of these findings remain weak, primarily because of 
the likelihood of selection bias and analytical issues. However, these findings clearly suggest a need 
to explore blood pressure trajectories longitudinally at population level, as changes in blood 
pressure over time could be significantly associated with a change in the risk of death 
12,32,35,36,41,139,142-147
. This would have important implications for clinical practice, as it would imply 
that a rapid change in blood pressure, whether a consequence of medical treatment or due to 
physiological changes, could be a predictor of higher mortality in people with T2DM. In this 
analysis, with a large cohort of patients who have had diabetes for at least 3 years, and whose data 
are available from the Clinical Practice Research Datalink (CPRD), the aim was to explore blood 
pressure trajectories over time and their association with mortality risk. 
5.2: Methods 
5.2.1: Data 
The Clinical Practice Research Datalink (CPRD) is one of the largest proprietary, anonymised 
longitudinal data sets derived from United Kingdom primary care. This database contains clinical 
information including diagnoses, mortality, laboratory results and prescription data (Chapter 3). The 
primary data set for this retrospective cohort study was derived from 84596 individuals aged 18 to 
99 who had been newly diagnosed with T2DM between January 1990 and December 2005, 
followed until April 2007, and who had been registered with the general practice for at least 12 
months. 
Clinical and laboratory measures for all individuals were arranged on the basis of 6-monthly 
windows, providing 6-monthly longitudinal data during the whole period of follow-up. The cohort 
for this study was selected under the following conditions: the patients should have had diabetes for 
at least 3 years with no missing anthropometric and clinical measure data at the time of diagnosis, 
and complete data was present for the last four 6-monthly (two year period) measurements of both 
systolic and diastolic blood pressure immediately before death or censoring. A dataset of 18583 
patients satisfying these conditions was used to explore the longitudinal trajectory of blood pressure 
during the two years immediately before death or censoring. Patients with a diagnosis of heart 
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failure either prior to their diagnosis with T2DM or during follow-up were excluded to avoid 
reverse causality, because patients who have experienced heart failure are very likely to have lower 
blood pressure levels than those who have not. 
The following information was extracted: age, gender, smoking status (defined as current, former or 
never smoker), BMI, blood pressure recordings (systolic and diastolic), HbA1c, history of CVD 
before the diagnosis of diabetes, and the recorded clinical events during follow-up, which included 
CVD (myocardial infarction, stroke, angina, coronary heart disease, peripheral arterial disease, 
angioplasty and coronary artery bypass graft), along with the dates of these events. Detailed 
information regarding the use of anti-hypertensive and cardio protective medications (including 
ACE inhibitors, beta blockers, statins and other concomitant medications) was obtained from 
prescription data, together with dates. Dates of death were derived from modified CPRD death 
codes. Specific disease Read codes capture data as part of routine care (including investigations) or 
as a result of hospitalisation or emergency care 
120,122-124
. Ethics approval for the use of CPRD data 
was granted by the Independent Scientific Advisory Committee in June 2014. 
5.2.2: Statistical Methods 
Summary statistics were presented by number (percentage), mean (SD), or median (IQR), as 
appropriate. Calculations of the median (IQR) duration of diabetes were based on the time from 
diagnosis of T2DM to the time at which the first of the last four blood pressure measurements were 
taken. The average duration of follow-up was calculated from the time of diagnosis of diabetes to 
the end of the follow-up period. 
To compare the longitudinal trajectory levels of systolic and diastolic blood pressure by mortality 
status, generalised estimating equation (GEE) regression models were used with approximately 
normally distributed blood pressure measurements and ‘unstructured’ correlation patterns among 
the longitudinal measurements 
148
. Multivariate GEE models were fitted with adjustments for age, 
sex, duration of diabetes, history of CVD, BMI and HbA1c at diagnosis, current CVD events, anti-
hypertensive and cardio protective medications. 
To evaluate the effects of changes in systolic and diastolic blood pressure on mortality risk, over 
two years, mixed-effects logistic regression models were fitted, with adjustments for the risk factors 
described above. Separate models were fitted for all patients and for patients with and without a 
history of CVD (except heart failures). 
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Systolic and diastolic blood pressures were categorized into blocks of 10 mmHg and 5 mmHg 
respectively, to evaluate the mortality risks associated with different levels of blood pressure over 
time. Odds ratios and their bootstrapped 95% confidence intervals were obtained. To evaluate the 
interaction effects of age and blood pressure (continuous measures) on mortality risk, interaction 
parameters were included in the logistic regression models, and probabilities of death, along with 
their 95% confidence intervals, were plotted against blood pressure measurements on a two-
dimensional plane. 
5.4: Results 
In the cohort of 18583 patients who had four consecutive 6-monthly (2 years) blood pressure 
measurements taken in the period before death or censoring, 53% were male, 13% were smokers, 
the mean (SD) age was 67 (11) years, 22% (n=4,164) had had at least one cardiovascular event 
before their diagnosis of diabetes, and 21.5% (n=3,999) had had at least one cardiovascular event 
during the course of 6.8 years of median follow-up. Cardiovascular events included non-fatal MI, 
stroke, CHD, PAD, angina, angioplasty and CABG. The mean (SD) age of this cohort at the time of 
diagnosis with diabetes was 62 (11) years. Over a median follow-up period of 6.8 years from the 
time of diagnosis of diabetes, 1025 (5.5%) patients died (Table 5.1). 
 
Table 5.1: Descriptive statistics of the study cohorts, at the time of diagnosis. 
 
Without Previous 
CVD 
With Previous 
CVD 
All Patients 
N 14419  4164  18583  
Age at Diagnosis (years) 61 (12 ) 66 (10) 62 (11) 
Male
#
 7369 (51.1)  2538 (61.0)  9907 (53.3)  
Smoking status    
Ex-smoking 4896 (34.2) 1815 (43.8) 6711 (36.3) 
Current smoking 1786 (12.5) 552 (13.3) 2338 (12.7) 
Age < 68
#
(years) 7431 (51.5) 1446 (34.7) 8877 (47.8) 
Age ≥ 68#(years) 6988 (48.5) 2718 (65.3) 9706 (52.2) 
Duration of Diabetes (years)
$
* 4.0 (3.0, 6.5) 4.0 (3.0, 6.5) 4.0 (3.0, 6.5) 
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SBP (mmHg) 139 (16) 139 (17) 139 (16) 
 <130 mmHg 3177 (22.0) 994 (23.9) 4171 (22.4) 
 130-140 mmHg 3918 (27.2) 1062 (25.5) 4980 (26.8) 
 ≥140mmHg 7324 (50.8) 2108 (50.6) 9432 (50.8) 
DBP (mmHg) 78 (9) 76 (10) 77 (10) 
 <80 mmHg 7004 (48.6) 2420 (58.1) 9424 (50.7) 
 80-85 mmHg 4320 (30.0) 1102 (26.5) 5422 (29.2) 
 ≥85 mmHg 3095 (21.5) 642 (15.4) 3737 (20.1) 
BMI (kg/m
2
) 30.5 (6.0) 30.0 (5.7) 30.4 (6.0) 
HbA1c (%) 8.0 (2.0) 7.8 (1.9) 7.9 (2.0) 
Duration of Follow-up*(years) 6.8 (5.3, 9.4) 6.9 (5.4, 9.6) 6.8 (5.3, 9.4) 
Current CVEs    
MI 75 (0.5) 599 (14.4) 674 (3.6) 
Stroke 318 (2.2) 819 (19.7) 1137 (6.1) 
PAD 12 (0.1) 664 (15.9) 676 (3.6) 
CHD 915 (6.3) 1137 (27.3) 2052 (11.0) 
Angina 1327 (9.2) 657 (15.8) 1984 (10.7) 
Angioplasty 102 (0.7) 141 (3.4) 243 (1.3) 
CABG 122 (0.8) 187 (4.5) 309 (1.7) 
Any cardiovascular event 1724 (12.0) 2275 (54.6) 3999 (21.5) 
Current medications    
Metformin  10912 (75.7) 2955 (71.0) 13867 (74.6) 
Sulphonylurea  7912 (54.9) 2381 (57.2) 10293 (55.4) 
Rosiglitazone 2615 (18.1) 581 (14.0) 3196 (17.2) 
Pioglitazone 992 (6.9) 242 (5.8) 1234 (6.6) 
Any oral anti-diabetes drug 12076 (83.8) 3401 (81.7) 15477 (83.3) 
Insulin 2130 (14.8) 754 (18.1) 2884 (15.5) 
Statins 11959 (82.9) 3795 (91.1) 15754 (84.8) 
ACE/ARB 11324 (78.5) 3588 (86.2) 14912 (80.2) 
Betablockers 5443 (37.7) 2630 (63.2) 8073 (43.4) 
   
76 
 
Hypertensive medications 12094 (83.9) 3897 (93.6) 15991 (86.1) 
All-Cause Mortality
#
 694 (4.8) 331 (7.9) 1025 (5.5) 
*Median (IQR),
 #
No. (%), 
$
Measurements at the start of the cohort 
Recorded vascular events during the follow-up period, along with a record of medication history, 
are presented in Table 5.1. The proportion of patients with a history of previous cardiovascular 
event(s) was higher in those who died (32%) compared to those who remained alive (22%). The 
proportions for any cardiovascular event(s) during the follow-up were 44% and 20% respectively 
for those who died and for those who remained alive. The proportion of patients with both previous 
and current cardiovascular events was significantly higher (25%) in those who died compared to 
those remained alive (11.5%). Most patients in the cohort (86%) were taking anti-hypertensive 
medications (ACE/ARB or beta blocker) for a median (IQR) prescription duration of 5 (3, 6) years. 
Blood pressure trajectories are plotted in Figures 5.1 and 5.2, using mean (95% CI) values. Overall, 
these 2-year trajectories clearly suggest significantly higher blood pressure levels in those who died 
(Table 5.2). Patients who died, on average had significantly higher systolic blood pressures, by 5 
mmHg (95% CI: 3-6 mmHg), and diastolic blood pressures, by 1 mmHg (95% CI: 0.1 - 2.1 
mmHg), before death, compared to those who remained alive. These estimates were adjusted for 
various factors, as described in the methods section. Male patients had consistently lower systolic 
blood pressures during the two year period, compared with females – by 1 mmHg (p < 0.01) on 
average. However, male patients had marginally higher diastolic blood pressure trajectories during 
the follow-up period. Age and duration of diabetes were statistically significant contributing factors 
to higher systolic blood pressure trajectories. 
Table 5.2: The effects of risk factors on longitudinal measures of blood pressure over the two 
year period immediately before death or censoring 
 
Variable 
Regression Coefficient 
(95% CI) 
P-value 
SBP 
Dead vs. Alive 4.4 (2.5, 6.3) <0.01 
Age(years)* 0.23(0.20, 0.26) <0.01 
Duration of Diabetes 0.18 (0.04, 0.31) <0.01 
Male -0.70 (-1.2,-0.12) 0.01 
Baseline BMI 0.10 (0.05, 0.15) <0.01 
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Baseline HbA1c  0.30 (0.12, 0.41) <0.01 
Hypertensive Medications 5.7 (4.9, 6.5) <0.01 
Cardio protective medications -1.00 (-2.75, 0.75) 0.26 
 CVD prior to diagnosis -2.4 (-3.35, -1.50) <0.01 
 CVD during follow-up -1.9 (-3.0, -0.76) <0.01 
 
CVD in both prior and during 
follow-up 
-1.8 (-2.79, -0.71) <0.01 
    
 
 
DBP 
Dead vs. Alive 1.1 (0.11, 2.1) 0.03 
Age(years)* -0.19 (-0.20, -0.17) <0.01 
Duration of Diabetes -0.14 (-0.22, -0.07) <0.01 
Male 0.76 (0.42, 1.10) <0.01 
Baseline BMI  0.15 (0.12, 0.18) <0.01 
Baseline HbA1c 0.04 (-0.04, 0.13) 0.31 
Hypertensive Medications -1.28 (0.80, 1.75) <0.01 
Cardio protective medications -0.27 (-1.40, 0.85) 0.63 
 CVD prior to diagnosis -1.31 (-1.83, 0.78) <0.01 
 CVD during follow-up -1.31 (-2.01, -0.60) <0.01 
 
CVD in both prior and during 
follow-up 
-2.19 (-2.80, -1.58) <0.01 
*at start of the study; GEE model: SBPit or DBPit ~ Agei + Sexi + Duration of Diabetes i + Baseline 
BMI + Baseline HbA1c + Anti-hypertensive Medications + Cardio protective medications+ CVD 
status+ Eventi; i for subject, t for time 
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Figure 5.1: Mean (95% CI) of longitudinal measures of systolic blood pressure during the two 
year period prior to death or censoring 
 
Figure 5.2: Mean (95% CI) of longitudinal measures of diastolic blood pressure during the 
two year period prior to death or censoring 
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Patients taking anti-hypertensive medications had significantly higher systolic blood pressures – by 
about 6 mmHg during the two year period before death or censoring – but no clinically meaningful 
difference was observed in diastolic levels. Patients with a systolic/diastolic blood pressure 
consistently above 130/80 mmHg for the two years before the event had a significantly increased 
mortality risk – by 52% (odds ratio: 1.52; 95% CI: 1.25, 1.84) and 95% (odds ratio: 1.95; 95% CI: 
1.76, 2.16) in younger and older patients, respectively. 
Systolic blood pressure during the two year period immediately before death or censoring was 
higher by 2 mmHg (p < 0.01) in those who experienced at least one stroke during the follow-up. 
The proportions of patients with a prior or current history of non-fatal stroke in the cohort were 5% 
(n=850) and 6% (n=1337), respectively. Of the patients who had a prior history of stroke, 86% 
experienced at least one event of stroke during the follow-up. 
Adjusting for risk factors, including blood pressure, patients who experienced at least one non-fatal 
stroke (6%, n=1137) and non-fatal MI (4%, n=674) during the follow-up period had three-fold 
(odds ratio: 2.7, CI: 2.2, 3.2) and four-fold (odds ratio: 4.1, CI: 3.3, 5.1) increased mortality risks, 
respectively. 
Compared to patients with a systolic blood pressure between 130-139 mmHg during the two year 
period immediately before death or censoring, patients with higher systolic blood pressures had a 
significantly higher mortality risk (Table 5.3). This higher mortality risk pattern was similar for 
patients with and without a history of CVD. Overall, patients with a systolic blood pressure below 
110 mmHg had a 56% increased mortality risk. 
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5.5: Discussion and Conclusions 
This population-based analysis of blood pressure trajectories prior to death provides new 
information on the dynamics of blood pressure in patients with T2DM with median (IQR) duration 
of 4.0 (3.0 - 6.5) years. Both systolic and diastolic blood pressure trajectories were higher for the 
two year period before death. In patients who died, the adjusted systolic blood pressure trajectories 
were higher, by 7 mmHg (95% CI: 6-8 mmHg) and 6 mmHg (95% CI: 4-8 mmHg), in age groups 
above and below 68 years, respectively. In older patients who died, diastolic blood pressure 
trajectories were higher, on average by 3 mmHg (95% CI: 2-3.3 mmHg), compared to those who 
remained alive. For patients younger than 68 years, there was a significant difference in the 
diastolic blood pressure trajectories between those who died and those who were alive, by 1 mmHg, 
although this may not be a clinically important difference. While several studies have reported a fall 
in diastolic blood pressure with aging
149-151
, these studies did not model the dynamics of this inverse 
relationship longitudinally in relation to the mortality risk of patients with T2DM. 
Significantly increased mortality rates were observed in patients experiencing one or more 
cardiovascular events. Among those who died, 13%, 17% and 44% had experienced at least one MI, 
stroke, and any cardiovascular event, respectively, during the follow-up period. Several studies, 
including the ACCORD trial and the recent meta-analysis by McBrien et al. (2012), have reported a 
reduced risk of stroke at lower systolic blood pressure levels 
12,36,137
. McBrien et al. (2012) reported 
a significant 35% risk reduction (relative risk: 0.65; 95% CI: 0.48 – 0.86) for stroke in patients 
treated with an intensive blood pressure lowering strategy (systolic/diastolic: 130/80 mmHg) 
compared to treatment with standard blood pressure targets (systolic/diastolic: 140-160 / 85-100 
mmHg). In this analysis, older patients with systolic/diastolic blood pressures above 130/80 mmHg 
and above 140/80 mmHg respectively had 12% (95% CI of odds ratio: 1.02 - 1.22; p=0.019) and 
14% (95% CI of odds ratio: 1.04 - 1.26; p=0.007) significantly increased risks of stroke. However, 
systolic and diastolic blood pressures were not significantly associated with stroke in patients under 
68 years. 
Rogers et al. (2011) reported a significantly higher decline in mean systolic blood pressure, by 3.2 
mmHg/year, in T2DM patients who died, compared to a decline of 0.7 mmHg/year in those who 
were alive 
141
. In the present study, using a more comprehensive data set and complete consecutive 
blood pressure measurements available for the duration of the year immediately before death or 
censoring, no clinically significant decline in blood pressure was observed before death. 
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Key strengths of this analysis include a large cohort of individuals with T2DM from routine clinical 
practice with a median follow-up of about 7 years, complete (non-missing) longitudinal blood 
pressure data, detailed information regarding medications and cardiovascular events, and a focus on 
mortality. With consecutive 6-monthly longitudinal data on systolic and diastolic blood pressure 
immediately before death or censoring, for more than 18583 patients over a 2 year period, and a 
5.5% death rate, the study had sufficient statistical power to make robust inferences about the 
trajectory levels of blood pressure by mortality. Further, information was available on the duration 
of treatment with anti-hypertensive and other cardio protective medications, as well as the 
occurrence and timing of cardiovascular events; these were useful in generating robust conclusions. 
To reduce possible selection bias, patients who had had diabetes for a minimum of 3 years were 
chosen for the analysis. The use of sophisticated modelling techniques, to account for time-varying 
measurements of risk factors, added further strength to the robustness of the estimates obtained in 
this analysis. Analytical approaches allowed for dynamic clinical data with skewness and high 
longitudinal variability. 
The limitations of this study include the non-availability of (1) data on heart rate; (2) data on 
adherence to medications, during the follow-up period; and (3) data on ethnicity. In addition, 
adherence to the study protocol for collecting biomedical and anthropometric measurements was 
inconsistent. However, these issues are unlikely to affect the robustness of the results of this study 
due to the large sample size, and the alignment of longitudinal data in time-windows. 
In conclusion, the population level analyses of blood pressure trajectories leading up to death 
provide clear messages for intensive blood pressure control and related management policies in 
primary care. The findings suggest that people with T2DM who died have a more rapid decline in 
blood pressure in the period before death than people who remained alive, but this decline was not 
clinically significant. Increased mortality risks were observed with both higher and lower levels of 
SBP and DBP. Patients are reviewed at least annually in primary care and these findings provide 
further support for continued monitoring and blood pressure in people with T2DM to be tightly 
controlled. These findings should be considered in future iterations of clinical practice guidelines. 
 
 
 
 
   
85 
 
 
 
 
 
 
 
 
 
 
Chapter 6. Obesity Paradox in Type 2 Diabetes Mellitus  
This chapter was published as “Thomas G, Khunti K, Curcin V, et al. Obesity paradox in people 
newly diagnosed with type 2 diabetes with and without prior cardiovascular disease. Diabetes, 
obesity & metabolism 2014;16:317-25”  
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Obesity Paradox in People Newly Diagnosed With Type 2 Diabetes With and Without 
Prior Cardiovascular Disease 
 
 
6.1: Background 
Type 2 diabetes mellitus is a metabolic disease which accounts for over 90% of people with 
diabetes 
19,54
. Although the majority of these patients may belong to the obese category
70 
based on 
their body weight, recent studies have raised the issue of “obesity paradox” in patients with T2DM 
71,72
. Carnethon et al. (2012)
72
, in a recent study reported increased mortality in adult patients with 
normal body weight at the time of diagnosis of diabetes. Using pooled data from five studies 
(n=2625), the study reported that patients with normal body weight (BMI < 25 kg/m
2
) at the time of 
diagnosis of T2DM had 52% significantly increased risk of cardiovascular death and two-fold 
increased risk of all-cause mortality, compared to overweight (BMI ≥ 25 kg/m2 and < 30 kg/m2) or 
obese (BMI ≥ 30 kg/m2) patients 72. Although this study looked at some of the relevant risk factors 
while evaluating the risks in normal weight patients compared to overweight or obese, the study did 
not account for the possible interactions between the cardiovascular and glycaemic risk factors. In 
addition, due to the relatively small sample size, the robustness of the inferences is weak and hence 
the generalisation of the findings warrants further explorations. 
Lague et al. (2013)
152
, using a large Scottish cohort evaluated the association of BMI within one 
year of diagnosis of T2DM with the risk of cause-specific mortality, separately for men and women. 
Using BMI 25 to < 30 kg/m
2
 as a reference group, they reported 22% and 32% increased mortality 
risk in men and women respectively with BMI ranging between 20 to 25 kg/m
2
. Although the study 
excluded death within two years of diagnosis of T2DM, the differential risks among patients with 
and without the history of cardiovascular diseases were not evaluated. 
Two other studies, Translating Research Into Action for Diabetes (TRIAD)
153
 and the PROactive 
study
154
, reported increased mortality risk in established T2DM patients who were normal weight at 
the start of the study or lost weight during the follow-up. Although the “obesity paradox” is well 
studied in some other diseases including chronic kidney disease
155-159
, little is known about the 
association of normal body weight at the diagnosis of diabetes with cardiovascular risk and 
mortality. 
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Nevertheless, these studies have made important contributions to encourage research to explore the 
“obesity paradox” in patients with T2DM. Separately for patients with and without history of 
cardiovascular diseases before the diagnosis of T2DM, the aims of our study were: 
1. to explore the rates of cardiovascular events (CVE) and all-cause mortality in a large cohort 
of newly diagnosed people with T2DM among different BMI categories; 
2. to evaluate the risks of cardiovascular disease and mortality in normal weight and 
overweight patients compared to obese patients with adjustments for relevant risk factors; 
and to 
3.  evaluate the possible interactions of age, body weight and glycaemic level (measured by 
HbA1c) on cardiovascular risks and all-cause mortality. 
6.2: Research Design and Methods 
6.2.1: Data 
The General Practice Research Database (GPRD) is a large proprietary, anonymised longitudinal 
data sets derived from United Kingdom primary care. The GPRD contains clinical information 
including diagnoses, mortality, laboratory results and prescription data 
119,120
. The primary data set 
for this retrospective cohort study includes data from 84596 individuals aged 18 to 90 years with a 
new diagnosis of T2DM between January 1990 and April 2007, who had been registered with their 
general practice for at least 12 months 
121
. Rigorous classificaction techniques were used to ensure 
correct identification of patients with T2DM 
121,123
. The following information was extracted: age, 
gender, smoking status (defined as current, ex or never smoker), BMI, blood pressure recordings 
(systolic and diastolic), HbA1c, lipid measures, history of cardiovascular diseases before the 
diagnosis of diabetes and the recorded clinical events during follow-up included cardiovascular 
diseases (myocardial infarction, stroke, heart failure, angina, coronary heart disease, peripheral 
arterial disease, angioplasty and coronary artery bypass graft), diabetic neuropathy, renal 
complications along with dates of events. The date of death was derived from modified GPRD 
death codes. Specific disease Read codes capture data as part of routine care (including 
investigations) or as a result of hospitalisation or emergency care 
120,122-124
. 
A cohort of 47509 patients with newly diagnosed T2DM was selected for this study, who had 
complete information on age, sex, smoking status, deprivation score based on the Index of Multiple 
Deprivation
160,161
, BMI, HbA1c, blood pressure, and clinical (event) history before diagnosis and 
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during the follow-up. Only patients with BMI of 19 Kg/m
2
 or more were included. To eliminate the 
bias due to possible latent illness, we chose patients who did not experience any cardiovascular 
event or did not die within 2 years of diagnosis of diabetes. Of the cohort of 47509 patients, the 
number of patients with and without the history of cardiovascular diseases before diagnosis were 
10237 and 37272 respectively. 
6.2.2: Statistical methods 
The summary statistics were presented by number (percentage), mean (SD), or median (IQR), as 
appropriate. The median duration of follow-up was calculated from the time of diagnosis of 
diabetes to the end of the follow-up. Non-parametric Kruskal-Wallis test or the Chi-square test were 
used to compare different study parameters across the BMI categories. The death rates and their 
95% confidence intervals per 1000 person-years under different BMI categories were calculated 
using standard life-table analysis technique. 
To explore the association of BMI at diagnosis with the risk of CVE and all-cause mortality during 
follow-up, two different stratified Cox regression models were fitted: (1) simple model, adjusted for 
age, sex, smoking status, SBP, DBP, HbA1c and BMI categories; (2) extended model included 
LDL, HDL and triglyceride measures at diagnosis, apart from the variables included in the simple 
model. Stratified Cox regression model with “deprivation score” as the stratification factor was used 
because of the failure of the “proportionality assumption” associated with the covariates in the Cox 
regression models. The deprivation score identify the most deprived areas across the United 
Kingdom. It combines a number of indicators, chosen to cover a range of economic, social and 
housing issues, into a single deprivation score for each small area in the country. The indices are 
used widely to analyse patterns of deprivation. Additional analyses were conducted by matching 
age at diagnosis by BMI categories using the Censored Exact Matching method (a generalisation of 
Propensity Score method) 
162
. The bootstrapped and robust estimates of the confidence intervals of 
hazard ratios were obtained, and the quality of model fits were assessed using the Bayesian 
Information Criteria (BIC).
 
Age and HbA1c were categorised at their median levels. The categories of BMI were defined as 
“normal weight” (BMI> 18.5 kg/m2 & < 25 kg/m2), ‘overweight’ (BMI ≥ 25 & < 30 kg/m2) and 
‘obese’ (BMI ≥ 30 kg/m2). 
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6.3: Results 
In the cohort of 37272 patients without prior CVD (Cohort 1), 53% were male, 17% current 
smokers, mean (SD) age was 60 (13) years with 49% (n=18298) aged > 60 years (median age), 
BMI 30.8 (6.3) kg/m
2
 and HbA1c 7.9 (2.0)%. The proportions of patients in normal, overweight 
and obese categies were 15%, 36% and 49% respectively (Table 6.1). Younger patients (aged ≤ 60 
years) had higher BMI levels (mean BMI: 32.3 kg/m
2
) compared to the patients aged > 60 years 
(mean BMI: 29.1 kg/m
2
) (Figure 6.1). The distributions of all anthropometric, clinical and 
laboratory measures were significantly different across the BMI categories (Table 6.1). 
Table 6.1: Basic characteristics of study cohort by BMI Categories for patients without prior 
CVD 
 BMI Categories (kg/m
2
) 
 <25 ≥25 & <30 ≥30 All 
n (%) 5720 (15.3) 13347 (35.8) 18205 (48.8) 37272 
Age (Years)* 64 (13) 62 (12) 57 (12) 60 (13) 
 Age > 60
#
 3658 (64.0) 7603 (57.0) 7037 (38.7) 18298 (49.1) 
Men
#
 2968 (51.9) 8041 (60.2) 8735 (48.0) 19744 (53.0) 
Current smokers
#
 1026 (18.2) 1954 (14.8) 3108 (17.2) 6088 (16.5) 
Previous smokers
#
 1509 (26.7) 4453 (33.8) 5832 (32.4) 11794 (32.0) 
BMI(Kg/m
2
)* 22.8 (1.8) 27.5 (1.4) 35.6 (5.3) 30.8 (6.3) 
Deprivation Score
** 18.2 (9.9, 30.9) 17.8 (9.7, 30.9) 18.4 (10.5, 33.5) 18.2 (10.2, 32.7) 
SBP (mmHg)* 138 (20) 140 (18) 141 (18) 140 (18) 
DBP (mmHg)* 78 (10) 81 (10) 83 (10) 81 (10) 
HbA1c (%)* 8.1 (2.3) 7.9 (2.0) 7.9 (1.9) 7.9 (2.0) 
 HbA1c ≥7·5# 4131 (72.2) 9425 (70.6) 12784 (70.2) 26340 (70.7) 
LDL (mmol/L)* 2.9 (1.0) 3.0 (1.0) 3.0 (1.0) 3.0 (1.0) 
HDL (mmol/L)* 1.3 (0.4) 1.2 (0.3) 1.2 (0.4) 1.2 (0.4) 
Triglyceride 
(mmol/L) ** 
1.5 (1.0, 2.1) 1.8 (1.3, 2.6) 2.0 (1.4, 2.8) 1.8 (1.3, 2.6) 
# n(%)
 
* mean (SD) ** median (first quartile, third quartile) 
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In the cohort of 10237 patients with prior cardiovascular disease (Cohort 2), 61% were male, 15% 
current smokers, mean (SD) age was 67 (10) years with 46% (n=4725) aged > 68 years (median 
age), BMI 30.1 (5.7) kg/m
2
 and HbA1c 7.7 (1.9)%. The proportions of patients in normal, 
overweight and obese categies were 16%, 39% and 45% respectively (Table 6.2, p<0.01). Younger 
patients (aged ≤ 68 years) had higher BMI levels (mean BMI: 31.3 kg/m2) compared to the 
compared to the patients aged > 68 years (mean BMI: 28.6 kg/m
2
) (Figure 6.1).  
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Table 6.2: Basic characteristics of study cohort by BMI Categories for patients with prior 
CVD 
 BMI Categories (kg/m
2
) 
 <25 ≥25 & <30 ≥30 All 
n (%) 1623 (15.9) 4005 (39.1) 4609 (45.0) 10237 
Age (yrs)* 71 (9) 68 (10) 64 (10) 67 (10) 
 Age > 68
#
 1058 (65.2) 2024 (50.5) 1643 (35.6) 4725 (46.2) 
Men
#
 895 (55.1) 2674 (66.8) 2638 (57.2) 6207 (60.6) 
Current smokers
#
 271 (16.9) 584 (14.6) 657 (14.3) 1,512 (14.8) 
Previous smokers
#
 593 (36.9) 1783 (44.7) 2075 (45.2) 4451 (43.7) 
BMI(Kg/m
2
)* 22.9 (1.7) 27.5 (1.4) 34.8 (4.7) 30.1 (5.7) 
Deprivation Score
** 20.1 (10.2, 33.9) 20.1 (10.7, 35.0) 21.6 (11.6, 37.1) 20.7 (11.1, 35.0) 
SBP (mmHg)* 141 (21) 140 (19) 141 (19) 141 (19) 
DBP (mmHg)* 77 (11) 78 (10) 80 (11)  79 (11) 
HbA1c (%)* 7.6 (2.0) 7.7 (1.9) 7.7 (1.8) 7.7 (1.9) 
 HbA1c ≥7·5# 1092 (67.3) 2734 (68.3) 3169 (68.8) 6995 (68.3) 
LDL (mmol/L)* 2.6 (1.0) 2.6 (1.0) 2.6 (1.0) 2.6 (1.0) 
HDL (mmol/L)* 1.3 (0.4) 1.2 (0.3) 1.2 (0.5) 1.2 (0.4) 
Triglyceride 
(mmol/L) ** 
1.5 (1.1, 2.1) 1.8 (1.3, 2.5) 2.0 (1.4, 2.7) 1.8 (1.3, 2.6) 
# n(%)
 
* mean (SD) ** median (first quartile, third quartile) 
 
The median duration of follow-up was 5 and 5.6 years in Cohort 1 and Cohort 2 respective, and was 
similar across all BMI categories within individual cohort. In Cohort 1, 4.7% died of whom 82% 
were aged > 60 years (Table 6.3). The proportions of death in normal weight, overweight and obese 
patients were 8.1%, 5.1% and 3.4% respectively. The overall death rate was significantly higher 
among patients with normal weight (13.1/1000 person years) compared to higher BMI categories in 
this Cohort. Older patients (> 60 years) had all most 5-fold higher death rate compared to the 
younger patients, consistently over all BMI categories. During median 5 years of follow-up, 7.2% 
patients experienced atleast one CVE, and older patinets had significantly higher risk of CVE across 
all BMI categories (Table 6.3). Patients with BMI below 30 kg/m
2
 experienced significantly higher 
CVE (8%) compared to the obese patients (6.3%). 
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Table 6.3: Proportions and rates of events by BMI Categories for patients without prior CVD 
 BMI Categories (kg/m
2
) 
 <25 ≥25 & < 30 ≥30 All 
Follow-up 
duration (yrs)** 
5.2 (3.5, 7.8) 5.1 (3.5, 7.6) 4.9 (3.4, 7.0) 5.0 (3.4, 7.3) 
Current CVD
#
     
 Overall 463 (8.1) 1,070 (8.0) 1,146 (6.3) 2,679 (7.2) 
 Age ≤ 60 106 (5.1) 327 (5.7) 548 (4.9) 981 (5.2) 
 Age > 60 357 (9.8) 743 (9.8) 598 (8.5) 1,698 (9.3) 
     
Death
#
     
 Overall 462 (8.1) 683 (5.1) 617 (3.4) 1762 (4.7) 
 Age ≤ 60 55 (2.7) 101 (1.8) 163 (1.5) 319 (1.7) 
 Age > 60 407 (11.1) 582 (7.7) 454 (6.5) 1,443 (7.9) 
Death rate (95% CI) /1000 person years    
 Overall  13.1 (12.0, 14.4) 8.6 (7.9, 9.2) 6.0 (5.5, 6.5) 8.1 (7.7, 8.5) 
 Age ≤ 60 4.1 (3.1, 5.3) 2.8 (2.3, 3.4) 2.5 (2.2, 3.0) 2.8 (2.5, 3.1) 
 Age > 60 18.7 (17.0, 20.6) 13.2 (12.2, 14.3) 11.8 (10.7, 12.9) 13.8 (13.1, 14.6) 
# n(%)
 
** median (first quartile, third quartile) 
 
Among patients in Cohort 2, 12.8% died of whom 58% were aged over 68 years (Table 6.4). The 
proportions of death in normal weight, overweight and obese patients were 20%, 13.7% and 9.5% 
respectively. The overall death rate was significantly higher among patients with normal BMI 
(30.1/1000 person years) compared to higher BMI categories in this Cohort. Older patients (> 68 
years) had more than 2-fold higher death rate compared to the younger patients, consistently over 
all BMI categories. During median 5.6 years of follow-up, 52% patients experienced atleast one 
CVE, and normal weight patients had significantly higher incidence of CVE (59.3%) compared to 
the overweight (52.8%) and obese patients (48.8%). The CVE proportions were similar between 
younger and older patients across all BMI categories. 
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Table 6.4: Proportions and rates of events by BMI Categories for patients with prior CVD 
 BMI Categories (kg/m
2
) 
 <25 ≥25 & < 30 ≥30 All 
Follow-up duration 
(yr)** 
5.8 (3.8, 8.4) 5.7 (3.8, 8.2) 5.3 (3.7, 7.7) 5.6 (3.7, 8.0) 
Current CVD
#
     
 Overall 963 (59.3) 2115 (52.8) 2248 (48.8) 5326 (52.0) 
 Age ≤ 68 347 (61.4) 1068 (53.9) 1425 (48.0) 2840 (51.5) 
 Age > 68 616 (58.2) 1047 (51.7) 823 (50.1) 2486 (52.6) 
     
Death
#
     
 Overall 324 (20.0) 548 (13.7) 436 (9.5) 1308 (12.8) 
 Age ≤ 68 70 (12.4) 175 (8.8) 207 (7.0)  452 (8.2) 
 Age > 68 254 (24.0) 373 (18.4) 229 (13.9) 856 (18.1) 
Death rate (95% CI) /1000 person years    
 Overall  30.1 (27.0, 33.6) 21.1 (19.4, 22.9) 15.4 (14.0, 16.9) 20.1 (19.0, 21.2) 
 Age ≤ 68 16.3 (12.9, 20.6) 12.5 (10.8, 14.5) 10.9 (9.5, 12.5) 12.1 (11.0, 13.3) 
 Age > 68 39.2 (34.7, 44.3) 31.3 (28.3, 34.6) 24.5 (21.5, 27.8) 30.8 (28.8, 33.0) 
# n(%)
 
** median (first quartile, third quartile) 
 
Compared to patients with BMI > 30 kg/m
2
, normal weight patients had 47% (95% CI of HR: 1.29, 
1.69) and 30% (95% CI of HR: 1.11, 1.53) significantly higher mortality risk among patients in 
Cohort 1 and Cohort 2 respectively (Table 6.5 and Table 6.6). In Cohort 1, the increased mortality 
risk among the normal weight patients were similar between patients below and above the age of 60 
years (Table 6.5). However in Cohort 2, significant association of normal body weight (compared to 
obese patients) with mortality was observed only among older patients (95% CI of HR: 1.22, 1.82, 
p<0.001). The risk estimates for mortality associated with normal weight and over-weight patients 
were also similar for the age-matched cohorts. No increased CVE risk was observed in normal and 
overweight categories among patients in Cohort 1. However in Cohort 2, patients with BMI < 25 
kg/m
2
 had 13% higher risk of CVE (95% CI of HR: 1.03, 1.23, p=0.007) compared to the obese 
patients (Table 6.6). 
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The possible interaction effects of BMI seperately with age and HbA1c at baseline were evaluated 
using two approaches. First, for both cohorts, the interaction of these three risk factors 
(age×BMI×HbA1c) were statistically significant in time-to-event models for both CVE and all-
cause mortality. Secondly, we used the interaction of categories of age, BMI and HbA1c at 
diagnosis in the time-to-event analyses. In Cohort 1, compared to younger patients with obesity, 
younger patients with normal weight and older patients with normal weight had 48% and 7-fold 
significantly increased mortality risks respectively. A significant interaction between body weight 
and glucose levels was also observed in relation to the risk of mortality, after adjusting for other 
factors as described in the simple model. Compared to patients with HbA1c below 7.5% and BMI > 
30 kg/m
2
 at diagnosis of diabetes, normal weight patients with HbA1c < 7.5% and normal weight 
patients with HbA1c ≥ 7.5% had more than two-fold increased mortality risks respectively (HR: 
2.18 and 2.06 respectively). The interaction effect of BMI and HbA1c on the mortality risk is 
modified/affected by the distribution of age. This interaction effect was however not significant in 
relation to the risk of cardiovascular events.  
This exploration can be further considered with the concept of collider bias as depicted by Figure 
6.2. BMI and age are directly associated with HbA1c. These two factors collide with HbA1c which 
enhances the mortality risk. Aging and BMI are associated with mortality along different pathways 
as specified in Figure 6.2. 
Figure 6.2: Directed acyclic graph representing causal effects of BMI on mortality 
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Overall, older patients and smokers had significantly higher risks of CVE and all-cause mortality in 
both cohorts of patients. Men had significantly higher risks of CVE and death compared to women 
in both study cohorts. Men were on average 2 and 4 years younger than women in Cohort 1 and 
Cohort 2 respectively. As an additional exploration, we conducted separate analyses for men and 
women for both cohorts, to explore the risks of CVE and death associated with normal weight, 
compared to obese patients. No differences in risks in relation to normal weight were observed, 
compared to what we have observed with combined male-female data. 
Among patients without prior cardiovascular diseases, the proportions of current or ex-smokers in 
the normal, overweight and obese categories were 45%, 49% and 50% respectively. Compared to 
obese patients, the increased mortality risk in normal weight patients were similar between never 
smokers (HR,95% CI of HR: 1.38, 1.14-1.67) and current/ex-smokers (HR, 95% CI of HR: 1.60, 
1.33-1.94). After incorporating the occurrence of any cardiovascular event during the follow-up as a 
competing risk, the mortality risks associated with normal weight patients were higher by 51% 
(95% CI of HR: 1.29, 1.76) compared to the obese patients. It is therefore unlikely that residual 
confounding explains the association between smoking and mortality  
We explored the possible protective or deleterious effects of treatment with metformin and 
sulphonylurea in the study cohorts, while evaluating the association of BMI at diagnosis with the 
mortality risk. In Cohort 1, among patients treated with metformin within 6 months of diagnosis 
(n=24986), the proportion of death were significantly higher in the normal weight category (5.6%) 
and overweight category (4.1%), compared to those who were obese (3.1%). This provides strong 
evidence that the observed increased mortality risk associated with normal weight is independent of 
the protective effects of treatment with metformin. Among those treated with both metformin and 
sulphonylurea during follow-up (n=12444), the proportion of deaths was significantly higher in 
normal weight patients (4.6%) and overweight patients (2.6%), compared to obese patients (2.1%) 
(p=0.001). In patients treated with insulin during follow-up (n= 3490, Cohort 1), the proportions of 
death were significantly higher in normal weight patient (8.6%) and over weight patients (6.6%), 
compared to the obese patients (4.2%) (p<0.01). 
 6.4: Discussion and Conclusions 
In this study, using a large longitudinal primary care database with median follow-up of 5 years, we 
have addressed the recent controversial issue of the obesity paradox in the context of cardiovascular 
risks and all-cause mortality in patients with newly diagnosed T2DM. One of the novelties of this 
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study is the use of two separate cohorts of patients with and without the history of CVD prior to the 
diagnosis of diabetes. This study allows us to draw the robust epidemiological inferences that - (1) 
patients with normal weight at the onset of T2DM have significantly increased mortality risk, 
compared to obese patients; (2) the increased mortality risks in normal weight patients are evident 
in people both with and without previous history of cardiovascular diseases; (3) among patients 
without prior cardiovascular diseases, the increased mortality risks in the normal weight category do 
not differ statistically significantly between patients below and above the age of 60 years; (4) the 
increased risk of cardiovascular events in normal weight patients is only evident in those with 
previous history of cardiovascular diseases; (5) significant interaction of age, BMI and glycaemic 
level is evident in relation to risk of CVE and mortality among patients without prior cardiovascular 
diseases. 
The patterns of mortality risk associated with normal weight patients were similar between older 
and younger patients in the cohort without prior cardiovascular disease. However, among patients 
with prior cardiovascular disease (Cohort 2), the increased mortality risk associated with normal 
weight was evident only among patients with age over 68 years (HR: 1.49, p<0.01). The patterns of 
mortality risks associated with BMI categories were structurally different for the two age groups as 
evident from the hazard plots in Figure 6. 2, even after adjusting for the additive and interactive 
effects of other risk factors. The addition of other risk factors, as described in the extended model 
did not alter the findings from the simple model. 
 
 
 
1
0
2
 
  F
ig
u
re
 6
.3
: 
C
u
m
u
la
ti
v
e 
h
a
za
rd
 p
lo
ts
 f
o
r 
a
ll
-c
a
u
se
 m
o
rt
a
li
ty
 a
cr
o
ss
 t
h
e 
B
M
I 
ca
te
g
o
ri
es
 f
o
r 
a
ll
 p
a
ti
en
ts
 a
n
d
 b
y
 a
g
e 
ca
te
g
o
ri
es
 i
n
 c
o
h
o
rt
 w
it
h
o
u
t 
p
ri
o
r 
C
V
D
 
 
 
   
103 
 
The strengths of our study include: a large longitudinal primary care data with newly diagnosed 
T2DM; separate analyses for patients with and without prior history of cardiovascular disease; long 
median follow-up period of 5-years with about 286,000 person-years of follow-up; complete data 
on important risk factors; well identified and validated cardiovascular events and death with dates; 
and a robust analytical approach which accounts for the possible interaction effects between age, 
index of BMI and glycaemic levels in the incident diabetes patients, and a careful assessment to 
achieve the most robust risk estimates through the development of stratified Cox regression models. 
Some of these crucial aspects were not addressed in the important study recently published by 
Logue et al
152
 and Carnethon et al (2012) 
72
. The interaction effects of BMI and HbA1c at the 
diagnosis of diabetes in the context of the “obesity paradox” is a novel finding, and should 
encourage researchers to conduct further clinical and epidemiological studies in this field. 
The death rates in the study conducted by Carnethon et al
72
 on only 2652 incident diabetes patients 
were reported to be 28.5/1000 person-year and 15.2/1000 person-years respectively for normal 
weight and overweight plus obese patients. Among patients with/without prior cardiovascular 
diseases, our observed death rates in the normal, overweight and obese categories were 30.1/13.1, 
21.1/8.6 and 15.4/6.0 per 1000 person-years respectively. In addition, in older patients, the observed 
death rates among patients without prior cardiovascular diseases were about 5-fold higher in all 
BMI categories. Our observed all-cause mortality risks associated with normal weight patients for 
the two study cohorts are not directly comparable with other studies, as we have compared normal 
weight as well as overweight patients with the obese group, separately for patients with and without 
history of cardiovascular diseases before diagnosis of diabetes. Logue at al
152
 reported 22% and 
32% increased mortality risk associated with normal weight compared to overweight patients for 
males and females respectively. In our cohort of patients without a prior history of cardiovascular 
disease, these estimates were 21% (p=0.052) and 55% (p<0.01) respectively for male and female 
patients. 
In recent studies, Flegal et al.
156
 and Heymsfield et al.
155
 have discussed the limitations of using 
BMI as a marker of adiposity, and waist circumference is recommended as an additional surrogate 
marker of the health risks associated with adiposity. BMI as a marker of adiposity has its own 
weaknesses, and waist circumference is recommended as an additional surrogate marker of the 
health risks associated with adiposity 
155,156
. Some studies have suggested that individuals with 
normal body weight but high body fat (BF) content (called metabolically obese normal weight 
individuals) have a higher prevalence of cardiometabolic dysregulation and are at higher risk for 
cardiovascular mortality 
72
. A significant limitation of using BMI is its failure to differentiate 
between an elevated BF and preserved or increased lean mass, especially in patients with a BMI 
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below 30 kg/m
2
. However, BMI has many advantages as a surrogate of BF, such as simplicity and 
reproducibility, and is commonly used in most of the clinical and epidemiological studies as a 
measure of adiposity. The GPRD contains limited information on ethnicity, and on waist and hip 
circumference. Earlier studies have suggested that normal weight patients with T2DM could have a 
different genetic profile, which warrants a detailed ethnicity-based exploration 
163,164
. 
Smoking status is a potentially important modifier of the association between anthropometric risk 
factors, cardiovascular outcomes and all-cause mortality. We have used the ‘crude’ information on 
smoking status at the time of diagnosis of diabetes, as detailed information on duration, timing and 
change of smoking status during follow-up was not available. Although we had information on oral 
anti-diabetes drugs within 6 months of diagnosis of diabetes, we could not study the contributions 
of medications for other illnesses that could be associated with higher mortality. Another weakness 
of this study is the unavailability of the cause of death. 
Our population level exploratory study provides robust estimates of cardiovascular and mortality 
risks associated with normal body weight at the time of diagnosis of diabetes, but the possible 
mechanisms behind this are unknown 
71,72,165
. Some potential reasons have been discussed by 
Carnethon et al
72
, which include the possible existence of latent illness in patients with lower body 
weight that predisposes to mortality. We have explored two separate cohorts with and without the 
history of vascular diseases before diagnosis of diabetes, and also ensured that the possible bias due 
to existence of latent illness is eliminated by excluding patients with any cardiovascular event or 
death within two years of diagnosis. One approach to understanding the mechanism and the 
dynamics of this aspect would be to explore the trajectories of body weight, body fat and clinical 
risk factors over time during the follow-up in different BMI categories, after adequately taking 
account of the genetic factors and ongoing treatment regimens. In addition, further research needs to 
be focused on potential mechanisms for this association. 
In conclusion, patients with normal weight and overweight at the time of diagnosis of type 2 
diabetes have significantly increased rates and risk of mortality compared to the obese patients. 
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Chapter 7. HbA1c Trajectories by BMI at Diagnosis and the 
Effect of Multiple Imputation   
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Trajectories of HbA1c by body mass index and its association with mortality in patients with 
type 2 diabetes mellitus - a five year longitudinal population level study and the comparison of 
results with data obtained by multiple imputation 
7.1: Background 
Type 2 diabetes mellitus is a non-communicable metabolic disease. Individuals with this disease 
have a reduced life expectancy, and elevated risk of developing microvascular and macrovascular 
complications, as well as many other complications that can result in diminished quality of life 
1,11
. 
The occurrences of these complications are directly associated with the duration of the disease and 
the level of hyperglycaemia. The diagnostic criterion for identifying T2DM uses plasma glucose 
level or glycated haemoglobin (HbA1c), which is an average glucose level measured over a period 
of two to three months, rather than a single point value. 
The discovery of insulin was a major milestone in the history of T2DM. Since then, the primary 
goal in the treatment of patients with T2DM has been to normalise or near normalise blood glucose 
levels 
166,167
. Glucose lowering treatments must be increasingly intensified to sustain near-normal 
glycaemia because T2DM is a progressive disease with deterioration of β-cells over time 166. All 
patients with T2DM are advised to make lifestyle modifications to enhance weight loss and increase 
physical activity 
168-170
. 
Obesity is one of the most important modifiable risk factors for T2DM and the majority of patients 
with T2DM are overweight or obese 
171,172
. Body weight has a vital role in the prevention and 
treatment of patients with T2DM, because high body weight magnifies the characteristic feature of 
T2DM, insulin resistance. An overall increase in the number of obese individuals in both 
developing and developed countries has been associated with increasing prevalence of T2DM - 
more than 380 million people suffer from T2DM worldwide 
15
. As such, obesity is a major risk 
factor for T2DM 
173
. BMI is widely accepted and used as to identify obesity in individuals. 
Obesity has been proven to be an important risk factor among the complex array of contributory 
factors, for the development of T2DM and its associated atherosclerotic vascular complications 
66,67
. 
Contrary to the popular belief, studies have shown that in comparison to overweight or obese 
individuals, T2DM patients of normal weight are at a higher risk of atherosclerotic vascular disease 
and mortality associated with T2DM 
72,174
. There exists a subset of normal weight individuals with 
physiological characteristics of obese individuals and are prone to develop T2DM 
66,68
. They are 
denoted as metabolically obese but normal weight (MONW) patients and are characterised by a 
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confrontational metabolic status, which includes insulin resistance, hyperinsulinemia and other 
related diseases 
65,68
. This reiterates the fact that it is not necessary to be overweight or obese for the 
development and progression of T2DM. 
Glycaemic variation in T2DM patients, measured by HbA1c, over time according to BMI levels, 
remains understudied and its role in disease progression is not clear. One of the aims of this chapter 
is to explore the long-term longitudinal trajectories of HbA1c, by body mass index at the time of 
diagnosis of T2DM. 
It is also important to explore the relationships between HbA1c levels and complications associated 
with intensive treatment. Therapeutic strategies to control or reduce HbA1c levels in diabetic 
patients, thereby reducing complications associated with diabetes, has been supported by some but 
not all clinical trials 
175
. Data from epidemiologic studies and some clinical trials have been used to 
support guidelines for maintaining HbA1c or blood glucose levels in T2DM patients within or near-
normal levels, despite a lack of direct evidence concerning the risks and benefits of doing so 
13,28
. 
Analyses of data from the ACCORD trial have confirmed that an excessive all-cause mortality risk 
was associated with an intensive glycaemic treatment strategy in people with T2DM 
28
. However, 
epidemiologic studies suggest that greater degrees of hyperglycaemia in people with T2DM, 
reflected by elevated HbA1c levels, are associated with higher risks of both mortality and CVD. 
These risks have been estimated to increase by 18% (for CVD) and 12-14% (for mortality) for each 
1% increase in HbA1c 
7,28,176,177
. 
All trials addressed the effect of intensively controlling glycaemic levels and the benefits and risks 
associated with intensive therapy; other studies have evaluated CVD and mortality risks associated 
with intensive treatment in T2DM patients. However, none focused on the obesity status of 
individuals at the time of their diagnosis, nor did they address the modification of these changes by 
BMI status at the time of diagnosis. 
Inferences based on large longitudinal datasets are of great interest in the current research climate. 
One of the inherent problems associated with such datasets is missingness in the observations. 
Missingness in covariates may lead to various problems associated with the selection of variables, 
and diminished power and bias in the result estimates 
178
. In most randomised clinical trials, the 
‘last observation carried forward’ (LOCF) is a common approach for dealing with missing data 179. 
But in longitudinal observational studies, deletion of the cases with any missing values, called 
complete case (CC) analysis
179,180
, is often used. A detailed exploration of the technical and 
statistical challenges associated with missing data in clinical research is given in Chapter 2. 
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By considering these unmet immediate clinical and statistical needs, the aims of this cohort study 
were to: 
1. explore and compare the five year trajectories of HbA1c before death in T2DM patients 
classified as ‘normal weight’, ‘overweight’ or ‘obese’ at the time of their diagnosis. 
2. compare the mortality risk associated with intensive treatment and longitudinal HbA1c 
measurements immediately before death, within treatment groups, stratified by BMI. 
3. compare trajectories using the original data and the data obtained from multiple imputation. 
7.2: Methods 
7.2.1: Data 
The Clinical Practice Research Datalink contains the largest set of longitudinal primary care data 
derived from primary care practices in the United Kingdom. The CPRD contains clinical 
information including diagnoses, mortality, laboratory results and prescription of medications 
details 
120,181
. The primary data set for this retrospective cohort study includes data from 84596 
individuals aged between 18 and 99 who were newly diagnosed with T2DM in the period between 
1990 and 2005, followed up until April 2007, and who had been registered with the general practice 
for at least 12 months. Detailed information about the data is given in Chapter 3. 
To explore the trajectories of HbA1c and to assess the mortality risks of people in each of the BMI 
categories at the time of their diagnosis, a dataset of 7030 patients with T2DM was created based on 
the following inclusion criteria. 
Patients were diagnosed between 1 January 1990 to 1 December 2002, ensuring a minimum follow-
up of five years. They were also required to have: 
1. HbA1c measured at the time of diagnosis. 
2. BMI measured at the time of diagnosis. 
3. a minimum of six HbA1c measurements taken during the five years immediately before 
death or censoring; these were based on six-monthly longitudinal windows, thus ensuring 
more than 50% of the longitudinal data over the last 5 years before death/censoring. 
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Date of death was derived from modified GPRD death codes captured as part of routine care 
(including investigations) or as a result of hospitalisation or emergency care 
182
. Ethics approval for 
the use of CPRD data was granted by the Independent Scientific Advisory Committee in June 2014. 
The following information was extracted: demographic characteristics and factors, including age, 
gender, smoking status (defined as current, former or never smokers), BMI, blood pressure 
recordings (systolic and diastolic), HbA1c, previous and current clinical conditions included 
cardiovascular events (myocardial infarction, stroke, heart failure, coronary heart disease, peripheral 
artery disease, angina, angioplasty, coronary artery bypass graft), medication data by dates 
(including use of metformin, sulphonylurea, rosiglitazone, pioglitazone, meglitazone, insulin, 
ACE/ARB, beta blocker, statin and other concomitant medications) identified from prescription 
records, and all-cause mortality. Two new variables, named ‘any previous CVD’ and ‘any current 
CVD’, have been defined as composite outcomes measuring the occurrence of any CVD before 
T2DM diagnosis and any CVD during the follow-up period, respectively. 
Based on prescription data for oral anti-diabetes (OAD) drugs and insulin, the study population was 
classified into two groups: patients receiving intensive treatment, and those not receiving intensive 
treatment. Patients taking at least two OADs and insulin made up the intensive group. 
Categories of BMI were defined as ‘normal weight’ (BMI greater than 18 kg/m2 and less than 25 
kg/m
2), ‘overweight’ (BMI at least 25 kg/m2 and less than 30 kg/m2) and ‘obese’ (BMI at least 30 
kg/m
2
). The average duration of follow-up was calculated from the time of diagnosis with diabetes 
until the end of the follow-up period. 
7.2.2: Statistical Methods 
Summary statistics were presented by number (percent), mean (SD), or median (IQR), as 
appropriate. The chi-square test was used to assess relationships between categorical variables. One 
way analysis of varience (ANOVA), using the Bonferroni adjustment for multiple comprisons, was 
used to evaluate mean differences in clinical and biochemical parameters across BMI categories. 
Epanechikov Kernal density plots were used to plot the densities of HbA1c at the time of diagnosis 
within BMI categories. 
Separate multivariate GEE regression models were used, assuming approximately normally 
distributed HbA1c measurements and an unstructured correlation structure to evaluate longitudinal 
trajectories of HbA1c during the five years before death or censoring. This model was adjusted for: 
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the effects of age (using a cut-point of 65 years), sex, HbA1c at diagnosis, CVD status (no CVD 
either prior or during the follow-up period, previous CVD only, current CVD during follow-up 
only, CVD prior to diagnosis and during the follow-up period), CPM, and intensive treatment in 
normal, overweight and obese patients based on their BMI at the time of their diagnosis. Evaluation 
of mortality risk in these patients, according to their BMI status, was assessed with separate GEE 
models using a binomial distribution and an independent correlation structure after adjusting for: 
age, sex, HbA1c at diagnosis, CVD status, CPM, and intensive treatment. 
The number of missing HbA1c measurements was calculated for each time window, and, for their 
effect on the exploration of longitudinal trajectories, a comparison between multiply imputed data 
and original data was conducted. 
Multiple imputation is a simulation-based statistical technique consisting of three steps. 
1. An imputation step: following selection of a set of predictors for an imputation model, the 
required number of imputed datasets are created, in which predicted values under the model 
replace missing values. 
2. An estimation step: a specific statistical analysis is performed on each of the imputed 
datasets created by imputation. This step is also known as imputed data analysis. 
3. A pooling step: results obtained from different imputed data analyses are combined to form 
a single multiple imputation estimate, and to estimate the appropriate precision of this 
estimate, taking account between and within imputation variation. 
A total of 100 imputations were performed to impute the longitudinal values of HbA1c from the 
following covariates: age greater than 65 years, sex, baseline HbA1c, CVD status, cardio protective 
medications and intensive treatment. These imputed datasets are further analysed using statistical 
methods described above. The STATA syntax used for multiple imputations is given in Appendix 
2. 
7.3: Results 
7.3.1: Trajectories of HbA1c by BMI categories 
In the cohort of 7030 newly diagnosed T2DM patients, 54% were male, with a mean (SD) age of 61 
(11) years, BMI of 30.39 (5.91) kg/m
2
, and HbA1c of 8.2 (2.08)%. The proportions of normal 
weight, overweight and obese patients were 15% (n=1040), 39% (n=2778) and 46% (n=3212), 
respectively. Nearly 40% of patients were 65 or older, the majority of which were overweight 
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(n=1301, 45.7%) or obese (n=990, 34.8%) at the time of their diagnosis. Detailed descriptive 
characteristics of the study population are given in Table 7.1 
Table 7.1: Descriptive statistics of the T2DM study cohort 
 Normal Overweight Obese P value 
n 1040 2778 3212  
Age at Diagnosis (yrs) 64 (12) 63 (11) 58 (11)  
 Age ≥65 554 (53.3) 1301 (46.8) 990 (30.8) <0.001 
Male
#
 550 (52.8) 1722 (62.0) 1520 (47) <0.001 
Smoking status    <0.001 
 Never smokers
#
 566 (55.0) 1336 (48.0) 1545 (48.0)  
 Ex-smoker
#
 317 (30.6) 1116 (40.4) 1227 (38.4)  
 Current smoker
#
 152 (14.7) 311 (11.3) 425 (13.3)  
SBP (mmHg)* 141 (20) 142 (19) 144 (18)  
DBP (mmHg)* 80 (10) 81 (10) 84 (10)  
BMI (Kg/m
2
)* 22.9 (1.7) 27.5 (1.4) 35.3 (5.0)  
HbA1c (%)* 8.5 (2.3) 8.3 (2.1) 8.0 (2.0)  
LDL (mmol/L)* 3.4 (1.1) 3.3 (1.0) 3.2 (1.0)  
HDL (mmol/L)* 1.3 (0.4) 1.2 (0.3) 1.2 (0.7)  
Tryglyceride
**
 (mmol/L) 1.7 (1.2, 2.4) 1.9 (1.4, 2.8) 2.1 (1.5, 3.0)  
Previous Cardiovascular diseases    
Myocardial infarction
#
 41 (3.9) 88 (3.2) 88 (2.7) 0.14 
Stroke
#
 55 (5.3) 108 (3.9) 96 (3.0) <0.01 
Heart failure
#
 38 (3.7) 125 (4.5) 170 (5.3) 0.07 
CHD
#
 85 (8.2) 322 (11.6) 301 (9.4) <0.01 
PAD
#
 40 (3.9) 102 (3.7) 75 (2.3) <0.01 
Angina
#
 93 (8.9)  326 (11.7) 367 (11.4) 0.04 
Any Previous CVD
#
 240 (23.1) 679 (24.4) 695 (21.6) 0.03 
Current Cardiovascular diseases    
Myocardial infarction
#
 42 (4.0) 87 (3.1) 82 (2.6) 0.04 
Stroke
#
 69 (6.6) 149 (5.4) 135 (4.2) <0.01 
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Heart failure
#
 40 (3.9) 130 (4.7) 172 (5.4) 0.12 
CHD
#
 109 (10.5) 266 (9.6) 310 (9.7) 0.68 
PAD
#
 41 (3.9) 105 (3.8) 79 (2.5) <0.01 
Angina
#
 104 (10.0) 279 (10.0) 327 (10.2) 0.97 
Any Current CVD
#
 244 (23.5) 631 (22.7) 681 (21.2) 0.19 
Death
#
 50 (4.8) 118 (4.3) 114 (3.6) 0.14 
Current medication     
Metformin
#
 668 (64.2) 2210 (79.6) 2794 (87.0) <0.001 
Sulphonylurea
#
 752 (72.3) 1748 (62.9) 1725 (53.7) <0.001 
Rosiglitazone
#
 175 (16.8) 504 (18.1) 772 (24.0) <0.001 
Pioglitazone
#
 51 (4.9) 177 (6.4) 250 (7.8) <0.01 
Insulin
#
 219 (21.1) 407 (14.7) 489 (15.2) <0.001 
Beta blockers
#
 349 (33.6) 1124 (40.5) 1321 (41.1) <0.001 
ACEARB
#
 700 (67.3) 2091 (75.3) 2558 (79.6) <0.001 
CPM
#
 966 (92.9) 2667 (96.0) 3111 (96.7) <0.001 
Intensive treatment 171 (16.4) 361 (13.0) 434 (13.5) 0.02 
         *mean (SD), **median (Q1, Q3), 
#
n (%) 
Patients who were obese at their time of diagnosis with T2DM were younger than those who were 
normal weight or overweight, with a mean age of 58 (SD of 11). Higher HbA1c levels were 
observed in patients of normal weight (mean, SD: 8.5, 2.3) compared to those with higher BMIs. 
The density plots (by BMI status) of HbA1c at the time of diagnosis with T2DM are depicted in 
Figure 7.1. 
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Figure 7.1: Density plots of HbA1c (%) at time of diagnosis in normal, overweight and obese 
patients. 
 
The proportion of patients with a history of CVD prior to their diagnosis with diabetes was higher 
in overweight (n=679, 24%) and obese (n=695, 22%) patients compared with those of normal 
weights; these differences were significant across BMI categories (Table 7.1). 
Almost 22% (n=1556) of patients experienced at least one CVD after being diagnosed with T2DM; 
that is, during the follow-up period (Table 7.1). A total of 282 (4.01%) patients died. The proportion 
of deaths did not vary significantly across BMI categories. 
Metformin was the most prescribed anti-diabetic medication for those in the cohort, followed by 
sulphonylurea (Table 7.1). The proportion of those prescribed these medications varied significantly 
across BMI categories. Significantly higher proportions of overweight and obese patients were 
prescribed these medications compared to patients of normal weights. 
The trajectories of HbA1c over the five year period immediately before death or censoring – in 
normal, overweight and obese patients – varied significantly depending on the treatment strategy 
they were provided with. This information is presented graphically in Figure 7.2 
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Figure 7.2: Trajectories of HbA1c (%) over the 5 year period immediately before 
death/censoring, by treatment strategies. 
7.2a: Normal weight patients 
                         
 
Figure 7.2b: Overweight patients 
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Figure 7.2c: Obese patients 
 
The aim of intensive treatment with medication is to control (lower) glycaemic levels. However, 
patients receiving intensive treatments had significantly higher levels of HbA1c throughout the five 
years before death or censoring across all BMI categories. HbA1c levels of patients in the intensive 
treatment group fluctuated throughout the follow-up period. The multivariate model showed that 
patients undergoing intensive treatment had higher levels of HbA1c (%), for all categories of BMI – 
i.e. for patients who were overweight, obese, or of normal weight, by 1.07% (95% CI:1.02, 1.11), 
1.23% (95% CI:1.19, 1.28), and 0.94% (95% CI: 0.87, 1.01), respectively, after adjusting for the 
effects of other potentially confounding factors (Table 7.2). Older patients had significantly lower 
levels of HbA1c over the five years compared to their younger counterparts, across all BMI 
categories. Obese males had significantly higher HbA1c levels then obese females. High levels of 
HbA1c over the five years were associated significantly with the HbA1c level measured at the time 
of diagnosis with T2DM. Although HbA1c at the time of diagnosis contributed significantly to the 
higher levels of HbA1c over the five years before death or censoring, patients who were of a normal 
weight had higher levels of HbA1c compared to those who were overweight or obese (0.19 versus 
0.15 and 0.16) (Table 7.2). CVD status was not associated with HbA1c levels in patients who were 
of a normal weight. There were significant reductions in HbA1c levels in overweight and obese 
patients, although these reductions were of marginal clinical importance. Significant reductions (of 
marginal clinical importance) were also observed in overweight patients who experienced a CVD 
event prior to diagnosis and during the follow-up period. The same pattern of reductions were also 
observed in obese patients who experienced a CVD event during the follow-up period.  
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An overall exploration of the trajectories of HbA1c in patients who were of of normal weight, 
overweight and obese showed that differences in levels of HbA1c (measured longitudinally over 
five years) were not statistically significantly different between patients who died and those who 
remained alive. However, obese patients who died, or were censored at the end of the follow-up 
period, had significantly lower levels of HbA1c than those who remained alive (Figure 7.3). 
Figure 7.3: Trajectories of HbA1c by mortality status and baseline BMI 
Figure 7.3a: Normal weight  
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Figure 7.3b: Overweight  
 
Figure 7.3c: Obese  
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Analyses of the mortality risk associated with longitudinally measured HbA1c levels, and other 
covariates based on their BMI levels at time of diagnosis, are given in Table 7.3. These showed a 
14% increased mortality risk for every 1% increase in HbA1c over the five years immediately 
before death or censoring – for patients of a normal weight (OR, 95% CI: 1.14, 0.92-1.43). This 
increased mortality risk was clinically but not statistically significant. Overweight (OR, 95% CI: 
1.06, 0.94-1.21) and obese (OR, 95% CI: 1.02, 0.90-1.14) patients also had higher (but statisitically 
nonsignificant) risks, but compared to patients of a normal weight, the risks were lower – although 
still clinically significant (Table 7.3). Older patients had a significantly increased mortality risk 
compared to younger patients, across all BMI categories. Patients who were 65 years or older and of 
normal weight at the time of their diagnosis had an almost six fold increased mortality risk when 
compared to their younger counterparts (OR, 95% CI: 5.7, 2.29-14.35 ). Similarly, overweight and 
obese older patients had a five- and three- fold increased mortality risk compared to the younger age 
group, respectively (OR, 95% CIs: 4.7, 2.84-7.94, and 3.4, 2.26-5.20). 
In patients of normal weight, females had a two- fold significantly increased mortality risk 
compared to males, (OR, 95% CI: 2.04, 1.08-3.82). Patients who were prescribed cardioprotective 
medications during the follow-up period had a significantly reduced mortality risk across all BMI 
categories. Compared to patients who were free from CVD both prior to their diagnosis with T2DM 
and during the follow-up, those who had at least one episode of CVD during the follow-up and 
those who had had both previous and current episodes of CVD had higher mortality risks, for all 
BMI categories (Table 7.3). 
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7.3.2: Imputed data versus original data 
The proportions of missing data in the longitudinal measurements of HbA1c by BMI status are 
given in Table 7.4. During the last four years before death, the proportion of missing observations 
in HbA1c measurements were generally consistent in all three categories of BMI. However, during 
the last year – that is, the one immediately before death or censoring – this proportion increased by 
more than 50%, an effect that was similar for all BMI categories. 
Table 7.4: Proportions of missing data in HbA1c measured longitudinally in the 5 year period 
before death or censoring, according to BMI categories of the patients at the time of their 
diagnosis with T2DM. 
HbA1c 
(Longitudinal) 
Normal 
n(%) 
Overweight 
n(%) 
Obese 
n(%) 
-54 months 197 (18.9) 496 (17.9) 537 (16.7) 
-48 months 181 (17.4) 533 (19.2) 633 (19.7) 
-42 months 212 (20.4) 498 (17.9) 612 (19.1) 
-36 months 194 (18.7) 498 (17.9) 571 (17.8) 
-30 months 186 (17.9) 462 (16.6) 564 (17.6) 
-24 months 174 (16.7) 463 (16.7) 550 (17.1) 
-18 months 184 (17.7) 489 (17.6) 599 (18.7) 
-12 months 185 (17.8) 494 (17.8) 655 (20.4) 
-6 months 274 (26.4) 636 (22.9) 765 (23.8) 
Death/Censoring 533 (51.3) 1441 (51.9) 1676 (52.2) 
Analyses of HbA1c trajectories based on the multiply imputed datasets and the original data with 
missing HbA1c recordings is given in Tables 7.5 (7.5a – 7.5c). Comparison of these, which apply 
the same mode for the trajectories of HbA1c within BMI categories, shows similar estimates. This 
indicates that the original dataset with missing values was a representative sample of the complete 
longitudinal set of HbA1c measurements, at least for the purpose of this analysis. 
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Table 7.5: Comparison of the HbA1c trajectory in imputed data and original data 
Table 7.5a: Normal weight 
 MVNI   Original  
 Regression 
co-efficient 
P value Regression 
co-efficient 
P value 
Age ≥ 65 -0.24 (-0.29, -0.18) <0.001 -0.23 (-0.28, -0.17) <0.001 
Sex 0.01 (0.03, 0.06) 0.58 0.03 (-0.02, 0.08) 0.28 
HbA1c 0.18 (0.17, 0.19) <0.001 0.19 (0.18, 0.20) <0.001 
Prior CVD 0.01 (-0.08, 0.10) 0.85 0.02 (-0.07, 0.12) 0.63 
Current CVD 0.05 (-0.03, 0.14) 0.21 0.05 (-0.04, 0.15) 0.24 
Both CVD -0.06 (-0.14, 0.004) 0.06 -0.05 (-0.13, 0.02) 0.15 
CPM -0.08 (-0.17, -0.01) 0.09 -0.09 (-0.19, 0.02) 0.09 
Intensive treatment 1.23 (1.19, 1.28) <0.001 0.94 (0.87, 1.01) <0.001 
 
 
Table 7.5b: Overweight 
 MVNI  Original  
 Regression 
co-efficient 
P value Regression 
co-efficient 
P value 
Age ≥ 65 -0.23 (-0.26, -0.20) <0.001 -0.22 (-0.25, -0.19) <0.001 
Sex -0.01 (-0.03, 0.02) 0.74 -0.02 (-0.05, 0.02) 0.33 
HbA1c 0.15 (0.14, 0.15) <0.001 0.15 (0.14, 0.16) <0.001 
Prior CVD -0.01 (-0.07, 0.03) 0.47 -0.02 (-0.07, 0.03) 0.46 
Current CVD -0.03 (-0.08, 0.02) 0.29 -0.04 (-0.09, 0.02) 0.23 
Both CVD -0.09 (-0.14, 0.05) <0.001 -0.09 (-0.13, -0.04) <0.001 
CPM -0.16 (-0.24, -0.08) <0.001 -0.17 (-0.25, -0.09) <0.001 
Intensive treatment 1.08 (1.03, 1.12) <0.001 1.07 (1.02, 1.11) <0.001 
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Table 7.5c: Obese 
 MVNI  Original  
 Regression 
co-efficient 
P value Regression 
co-efficient 
P value 
Age ≥ 65 -0.25 (-0.28, -0.22) <0.001 -0.25 (-0.29, -0.22) <0.001 
Sex 0.06 (0.03, 0.09) <0.001 0.06 (0.03, 0.09) <0.001 
HbA1c 0.15 (0.15, 0.16) <0.001 0.16 (0.15, 0.17) <0.001 
Prior CVD -0.02 (-0.07, 0.03) 0.39 -0.01 (-0.06, 0.05) 0.85 
Current CVD -0.06 (-0.12, -0.01) 0.01 -0.07 (-0.13, -0.01) 0.02 
Both CVD -0.05 (-0.09, 0.01) 0.02 -0.04 (-0.09, 0.01) 0.11 
CPM -0.02 (-0.11, 0.05) 0.53 -0.01 (-0.10, -0.08) 0.82 
Intensive treatment 1.23 (1.19, 1.28) <0.001 1.23 (1.19, 1.28) <0.001 
 
7.4: Discussion and Conclusion 
This analysis of 7030 newly diagnosed T2DM patients from the UK primary health care practice 
database showed that longitudinally measured levels of HbA1c over the five years immediately 
before death or censoring were consistently higher in patients who received intensive treatment, 
irrespective of their BMI status at the time of diagnosis. That is, patients who were normal weight, 
overweight and obese at the time of diagnosis had higher levels of HbA1c, despite undergoing 
intensive treatment, which was aimed at reducing glycaemic levels to normal or near-normal levels. 
Changes in HbA1c levels over the five years immediately before death or censoring was not 
significantly different for patients who died and those who remained alive. While the amount of 
missing data in the longitudinally measured HbA1c values was about 20% at each time point 
(except for the last measurement), a comparison of HbA1c trajectories for the inputed data set and 
the original data showed a very similar pattern. 
The large sample size used – 7030 newly diagnosed T2DM patients for whom longitudinal 
measurements of HbA1c over the five years immediately before death or censoring – was the major 
advantage of this analysis. By ensuring, during data selection, that more than 50% of the 
longitudinal HbA1c measurements were present (at least 6 measurements over the ten possible 
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measurements in the six monthly windows for all 7030 patients), potential issues related to the 
missingness of data were minimised to a great extent. Complete data on covariates used in GEE 
analysis and multiple imputation was another strength. As mentioned above, although the number 
of missing HbA1c measurements for each of the time points was quite high, the trajectory analysis 
gave similar results using both imputed and original data, indicating that data were missing at 
random, at least for the purposes of this analysis. The prescription of medication data and the 
occurences of other diseases during the follow-up period helped ensure the CVD history of patients 
was more precise. The application of appropriate statistical methods – multivariate analysis 
adjusting for the effects of other confounding covariates – added additional strength to this analysis. 
The exploration of trajectories of HbA1c stratified by BMI categories at the time of diagnosis is a 
very novel concept, as the majority of the studies in this area have evaluated the mortality risks 
associated with weight gain, or the relationship between higher BMIs and transitions in glycaemic 
levels 
72,155,156,183
. 
The limitations of this study include the non-availability of data regarding: (1) dietary habits – to 
evaluate their association with disease progression, as dietary habits are directly associated with 
BMI; (2) compliance with medications during the follow-up period; (3) lifestyle modifications 
made by patients after their diagnosis with T2DM. 
Previous studies have reported that approximately 80% of patients with T2DM are overweight or 
obese 
184
. Intensive lifestyle modifications, including improving physical activity and medications, 
are of considerable importance for diabetic patients in the control of their glycaemic levels and the 
associated CVD risk factors 
185
. 
A study by Watson et al.
186
 that explored the changes in HbA1c, weight and BMI after the initiation 
of insulin treatment in T2DM patients reported that it had helped to improve glycaemic levels, 
across all BMI categories, in the six months after its administration; but for the period between six 
and 24 months little change occurred. This study also reported that obese patients required higher 
levels of insulin to control their glycaemic levels. However, two years after the initiation of insulin 
treatment, additional insulin supplements did not substantially improve glycemic levels as before. 
The trajectory analysis by BMI status of newly diagnosed T2DM patients, exploring the changes to 
HbA1c over the five years before death, demonstrates that patients undergoing intensive treatment 
had significantly higher levels of HbA1c compared to those who were not. Intensive treatment with 
insulin in T2DM patients is initiated when treatment with oral anti-diabetes drugs alone fails to 
achieve reductions of HbA1c to an expected level 
169
. The study design of Watson et al.
186
 clearly 
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states that study subjects included patients on oral therapy as well. Therefore, the treatment 
described can be considered as an intensive therapy, as it encompasses the administration of both 
oral anti-diabetes drugs and insulin. Watson’s study also reported that the attainment of glycaemic 
control was differently achieved within different BMI categories, and that 26-31% of obese patients 
had attained HbA1c 7.5% or lower, compared with 41% of patients of normal weight. This clearly 
suggests that intensive therapy could be more effective in the control of glycaemic levels of normal 
weight patients. Another study, by Carnethon et al., reports that adults who were of a normal weight 
at the time of their diagnosis with T2DM had higher mortality risks compared to overweight and 
obese adults 
72
. 
One of the most important challenges in longitudinal studies and randomised controlled trials is that 
a large amount of missing data, as a result of loss to follow-up, potentially results in reduced 
statistical power and considerable reductions in internal validity, if data are not missing completely 
at random (MCAR), with additional challenges associated with the analysis of incomplete data 
187
. 
The most popular method for handling missing data is multiple imputation. This process replaces 
missing values with values predicted under a statistical model derived from the known data. It has 
been demonstrated that multiple imputation is very efficient, even in cases where a relatively small 
number of imputations is used 
84,188
. In this analysis, a high number of imputations (100 
imputations) was used. A comparion of the results generated using these the imputed and original 
datasets has shown very similar findings. The design of this study minimised the amount of data 
missing, which is the best way to address this problem of missingness; however it cannot be 
completely avoided in real clinical research. 
This novel trajectory analysis not only confirms the general clinical belief that overweight and 
obese patients have higher HbA1c levels, but normal weight patients may also have much higher 
levels than are to be expected, even when treated with intensive therapies. The mortality risks 
associated with HbA1c were clinically significant for patients in all BMI categories. More clinical 
attention must be given to normal weight patients, for the better clinical management of this 
disease. 
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Chapter 8. General Discussion and Conclusions 
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8.1: Thesis Research Objectives 
The aims of this thesis are restated below: 
Objective 1: to evaluate the gender specific effects of smoking on cardiovascular and mortality 
outcomes in newly diagnosed diabetic men and women (Chapter 4). 
Objective 2: to examine blood pressure trajectories before death in patients with type 2 diabetes 
mellitus (Chapter 5). 
Objective 3: to examine the obesity paradox in people newly diagnosed with T2DM, with and 
without prior cardiovascular disease (Chapter 6). 
Objective 4: to examine HbA1c trajectories, by body mass index, and how these are associated with 
mortality in patients with T2DM; as well as to investigate the effects of missing data, using multiple 
imputation. (Chapter 7) 
Each of these objectives address important clinical questions associated with the management of 
T2DM (from the perspective of the disease being non-curable, but controllable, once diagnosed). 
This thesis is based on a statistical analysis of a large longitudinal study (17 year follow-up) of 
84596 newly diagnosed T2DM patients. Data was taken from the UK CPRD, which allowed 
changes in key indicators of disease progression – from diagnosis until death or censoring – to be 
tracked. Aspects of self-management and appropriate clinical care are described with reference to 
each of these objectives. Findings from each of the above mentioned objectives, and their relevance 
to the current clinical management of diabetes, are discussed in this chapter. 
Chapter 4 confirms the existence of gender disparities in relation to the effects of smoking in 
patients newly diagnosed with T2DM. Complications associated with T2DM considered in this 
analysis were CVD, as well as all-cause mortality. An increased risk of cardiovascular diseases and 
mortality was observed among women, based on comparisons among never smokers, former 
smokers and current smokers. These analyses were stratified by CVD history prior to diagnosis with 
T2DM, and CVD that developed during the follow-up period. Results were consistant with other 
studies that had explored gender differences in diabetic patients, in the risks associated with CVD 
and mortality attributable to smoking 
24,125,126
. The finding that diabetic women who smoked had 
higher coronary and mortality risks was consistent with previous researches 
24,76
. The reason for 
these higher risks, compared to men, is still unknown, although delays in diagnosis, or the sub-
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optimal clinical management of T2DM in women have been proferred as reasons. This analysis did 
not address the undertreatment of diabetes in women. However, a study by Wexler et al. has 
confirmed diminished diabetic treatment in women compared to men 
127
. 
Chapter 5 explores the longitudinally measured trajectories of both systolic and diastolic blood 
pressure, and their association with mortality risk in newly diagnosed T2DM patients. This analysis 
clearly shows that patients who died during the study had significantly higher systolic and diastolic 
blood pressures for the two years immediately before death or censoring compared to those who 
survived. A study by Rogers and collegues reported a clinically and statistically significant rapid 
decline in both measurements of blood pressure in diabetic patients who died compared to patients 
who remained alive 
141
. However, results of the present analyses are based on a substantially higher 
sample size (N = 18583) of patients newly diagnosed with T2DM, as well as complete blood 
pressure measurements taken immediately before death or censoring. A clinically significant 
decline in blood pressure was not seen, although trajectories were higher in patients who died 
compared to those who remained alive. 
Chapter 6 of this thesis addresses the obesity paradox in relation to the risks associated with CVD 
and mortality in patients newly diagnosed with T2DM 
174
. The obesity paradox has been defined as 
the presence of an increased risk of CVD or mortality in patients of a normal weight compared to 
obese patients. An exploration of this paradox was stratified accoding to CVD history – one of the 
innovations of this study. This analysis demonstrates that patients with a normal weight at the time 
of diagnosis with T2DM have a significantly increased mortality risk compared to those who were 
obese. This was observed both in patients with and without prior CVD. In those who were of a 
normal weight and had no prior CVD, older patients (categorised on the basis of age at diagnosis – 
above or below 60 years) were not statistically different from younger patients in their increased 
mortality risk. Results from these analyses, examining the association between all-cause mortality 
and BMI category, are not comparable to those from other studies, as risks in the present analyses 
were estimated in normal and overweight patients and compared to obese patients, stratified by 
previous CVD statuses. However a recent study by Logue et al. explored the relationship between 
BMI and mortality in T2DM patients, reported that males and females of normal weights had 
significantly increased mortality risks compared to overweight patients – by 22% and 32%, 
respectively 
152
. 
The clinical research question discussed in Chapter 7 is an exploration of HbA1c trajectories in 
response to treatment strategy, for different BMI categories at the time of diagnosis with T2DM, 
which is a novel approach. A statistical issue discussed in this chapter is the performance of the 
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multiple imputation method, assessed by comparing estimates obtained from analyses of the 
incomplete data set and an imputed data set, which estimated the missing values of the 
longitudinally measured variables. 
The trajectory analysis showed that patients who received intensive treatment had significantly 
higher levels of HbA1c over the five years immediately before death or censoring; this effect was 
observed for patients within each of normal, overweight or obese BMI categories at the time of 
diagnosis. Patients of a normal weight also had higher HbA1c levels, despite being intensively 
treated with medication(s) aimed at controlling (lowering) HbA1c. Analysis of the change in 
HbA1c over the five years immediately before death showed an increased mortality risk for those in 
each of the three BMI categories. These inceased risks were clinically, though not statistically, 
significant and are directly associated with the obesity paradox 
174
 in T2DM patients. The overall 
trajectories of HbA1c were not significantly different for patients who died and those who remained 
alive, within each of the BMI categories. However, in obese patients, HbA1c levels were 
significantly lower in those patients who died during the follow-up period. 
The novelty of this analysis and the uniqueness of the study is that, unlike most other studies which 
have explored mortality risks associated with weight gain and transitions of glycaemic levels within 
different categories of BMI 
72,155,156,183
, this study focused on the trajectories of HbA1c in each of 
these BMI categories. 
The adequacy of multiple imputation in dealing with missing data in clinical research was examined 
in relation to the HbA1c analyses. It has been shown that multiple imputation is a very effective 
method for dealing with missing data, even when a relatively small number of imputations are made 
84,188
. The original longitudinal data set of 7030 patients was missing almost 20% of the HbA1c data 
for each time point. However, when comparing results from the original data and the imputed data, 
these were very similar for both. This suggests that, despite its incompleteness, the dataset can 
provide useful insights into disease progression in diabetic patients 
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8.2: Limitatatios of This Thesis 
Some of the main limitations are described below. 
Data for some key variables were not available. These included: 
1. Ethnicity 
2. Changes in socio-economic variables over time 
3. More detailed data regarding lifestyle factors 
a. Smoking status over time, intensity of smoking, cigerettes per day 
b. Dietary habits 
c. Physical exercise 
4. Compliance with medication, doasages 
5. Cause-specific mortality 
The population of the United Kingdom is a mixture of many different ethnic groups 
189
. The 
analyses in this thesis could not account for the possible metabolic differences between ethnic 
groups, as well as differences in body structure. Socio-economic and demographic data were 
available for the time of diagnosis, but not for subsequent time points, so changes during the 
follow-up period could not be accounted for. 
It is the usual practice for clinicians to advise patients to make lifestyle changes, by modifying diet, 
exercise and smoking habits, for example. This dataset did not have information regarding any 
advice that was given or possible changes made by patients in response, and so these could not be 
included in analyses. Similarly, data concerning changes to smoking status were unavailable. It was 
therefore not possible to measure the protective effects of post-diagnosis smoking cessation in these 
diabetic patients. Information about the number of cigerettes smoked per day, as well as changes to 
smoking habits made, was not available, and so patients could not be categorised according to the 
intensity of their smoking. 
However, the major limitation of the thesis is that it was focused on macrovascular disease, and the 
microvascular complications of T2DM were not considered. Long term T2DM is associated with 
microvascular diseases, such as diabetic retinopathy and diabetic neuropathy. Similarly, changes in 
related biochemical parametes, such as serum creatinine and albumin over time, were not addressed. 
   
131 
 
8.3: Recommendations for Future Research 
The development of T2DM could occur as a result of an interplay between genes and environmental 
factors, which influences insulin producing cells in the body. T2DM is a chronic, metabolic 
disorder affecting vital systems of the body, such as the brain, liver, heart and kidneys. A complex 
interplay of various factors, such as age, smoking habits, alcohol consumption, dietary 
modifications, and adherence to clinical interventions, directly influence the glycaemic profile of a 
person who has been diagnosed with the disease. The clinical management of T2DM encompasses a 
variety of approaches, including lifestyle modifications and clinical interventions. The standard 
clinical treatment plan for T2DM is illustrated in Figure 8.1. 
Figure 8.1: Clinical management of T2DM 
190
 
 
This thesis outlines the increased risk of CVD and mortality for women who smoke. Although this 
research did not aim to explore the driving factors that cause these increased risks in women, they 
might be attributable to under-treatment or sub-optimal clinical management of diabetic women. 
Therefore, further research should be conducted to explore these reasons further. 
Body types and dietary intakes vary between different ethnic groups; further research is needed to 
examine these differences, so that clinical management of the disease can be improved. Changes in 
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glycaemic levels are also associated with socio-economic status, an effect that is possibly mediated 
by lifestyle patterns. Research should also aim to address glycaemic transitions, in relation to the 
overweight/obesity transition, with a lengthy follow-up time, so as to inform optimal clinical 
management of the disease. 
8.4: Conclusions 
The prevalence of T2DM is at an all-time high, leading to increased concern from patients, 
clinicians, researchers and policy makers. Although much research is being conducted in this field, 
victims of this disease and the number of complications associated with it are also increasing in 
both developed and developing countries. The objective of this thesis was to generate conclusions 
that will assist the scientific community and clinicians to provide better clinical management and 
improved quality of life for patients. 
Earlier diagnosis and appropriate clinical management of T2DM will result in increased survival 
and improved quality of life for patients. It is of great importance to maintain good control of blood 
pressure and glycaemic levels in T2DM patients, as this research has demonstrated that a higher 
mortality risk is associated with higher and lower blood pressures (SBP, DBP) and higher levels of 
HbA1c. The existence of the obesity paradox could be due to the overconfidence of patients who 
have a normal BMI at the time of their diagnosis with T2DM. Such patients may feel that they are 
at a low risk and therefore do not need to modify their lifestyles to the degree that an overweight or 
obese patient should. Clinicians must emphasise the chronic, but controllable, nature of this disease, 
and that only with proper lifestyle modifications and theraputic management can future risks be 
minimised. 
Overall, the findings suggest that more attention must be given to glycaemic and blood pressure 
controls in T2DM patients. Also, appropriate clinical management of the disease has to be ensured 
in women and patients of normal weight. Awareness of the potential benefits of smoking cessation, 
and the benefits of lifestyle changes, in relation to the increased chance of survival they offer, has to 
be enhanced. Further research, aimed at primary prevention and improved management and control 
of T2DM, is needed to reduce the incidence, prevalence, and complications of this multi-faceted 
disease. 
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Appendix 2: STATA syntax for multiple imputation 
set seed 4385 
mi set mlong 
mi register imp A1c1 A1c2 A1c3 A1c4 A1c5 A1c6 A1c7 A1c8 A1c9 A1c10 
mi  impute mvn A1c1 A1c2 A1c3 A1c4 A1c5 A1c6 A1c7 A1c8 A1c9 A1c10=AGEGE65 SEX 
HBA1C6 i.CVDINT CPM MT2, add(100) 
mi reshape long A1c, i(PTID) j(Index1) 
mi estimate: xtgee A1c AGEGE65 SEX HBA1C6 CPM i.CVDINT MT2 if bmi6cat==0, 
family(gaussian) link(identity) corr(ind) 
mi estimate: xtgee A1c AGEGE65 SEX HBA1C6 CPM i.CVDINT MT2 if bmi6cat==1, 
family(gaussian) link(identity) corr(ind) 
mi estimate: xtgee A1c AGEGE65 SEX HBA1C6 CPM i.CVDINT MT2 if bmi6cat==2, 
family(gaussian) link(identity) corr(ind) 
 
